var title_f19_53_20304="MRI of AC joint degeneration";
var content_f19_53_20304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of AC joint degeneration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MRI image of acromioclavicular (AC) joint above shows narrowing of the joint space (arrow) and a subchondral cyst of the acromion (bright circular lesion adjacent to joint space). The AC joint of this 41 year old patient was asymptomatic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20304=[""].join("\n");
var outline_f19_53_20304=null;
var title_f19_53_20305="Fibrous dysplasia femur";
var content_f19_53_20305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrous dysplasia of the proximal femur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sclerosis around a focus of fibrous dysplasia of the proximal femur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20305=[""].join("\n");
var outline_f19_53_20305=null;
var title_f19_53_20306="Verrucous skin lesions in blastomycosis";
var content_f19_53_20306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Multiple verrucous skin lesions caused by Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple verrucous lesions on the forearm of a 20-year-old man with blastomycosis. (Courtesy of Dr. Hector Bonilla.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD,&nbsp;Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20306=[""].join("\n");
var outline_f19_53_20306=null;
var title_f19_53_20307="Oxychlorosene: Patient drug information";
var content_f19_53_20307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxychlorosene: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33057?source=see_link\">",
"     see \"Oxychlorosene: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clorpactin&reg; WCS-90 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxychlorosene or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on affected part only.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12092 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20307=[""].join("\n");
var outline_f19_53_20307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204852\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013526\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013525\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013530\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013531\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013533\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013528\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013529\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013534\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013535\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33057?source=related_link\">",
"      Oxychlorosene: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_53_20308="Interferon gamma-1b: Drug information";
var content_f19_53_20308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Interferon gamma-1b: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/54/11109?source=see_link\">",
"    see \"Interferon gamma-1b: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actimmune&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Actimmune&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If severe reactions occur, modify dose (50% reduction) or therapy should be discontinued until adverse reactions abate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic granulomatous disease:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BSA &le;0.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1.5 mcg/kg/dose 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BSA &gt;0.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 50 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     (1 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     ) 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Previously expressed as 1.5 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     ; 50 mcg is equivalent to 1 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F183617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic granulomatous disease: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe, malignant osteopetrosis: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BSA &le;0.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1.5 mcg/kg/dose 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BSA &gt;0.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 50 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     (1 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     ) 3 times/week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F183608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F2934668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     If severe reactions occur, reduce dose by 50% or therapy should be interrupted until adverse reaction abates.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actimmune&reg;: 100 mcg (0.5 mL) [2 million units]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4419053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by SubQ injection into the right and left deltoid or anterior thigh.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce frequency and severity of serious infections associated with chronic granulomatous disease; delay time to disease progression in patients with severe, malignant osteopetrosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on 50 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     dose administered 3 times weekly for chronic granulomatous disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (52%), headache (33%), chills (14%), fatigue (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (14%), vomiting (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site erythema or tenderness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10%), abdominal pain (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (6%), arthralgia (2%), back pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports: Alkaline phosphatase elevated, atopic dermatitis, granulomatous colitis, hepatomegaly, hypersensitivity reactions, hypokalemia, neutropenia, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Additional adverse reactions noted at doses &gt;100 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     administered 3 times weekly: ALT increased, AST increased, autoantibodies increased, bronchospasm, chest discomfort, confusion, dermatomyositis exacerbation, disorientation, DVT, gait disturbance, GI bleeding, hallucinations, heart block, heart failure, hepatic insufficiency, hyperglycemia, hypertriglyceridemia, hyponatremia, hypotension, interstitial pneumonitis, lupus-like syndrome, MI, neutropenia, pancreatitis (may be fatal), Parkinsonian symptoms, PE, proteinuria, renal insufficiency (reversible), seizure, syncope, tachyarrhythmia, tachypnea, thrombocytopenia, TIA",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to interferon gamma,",
"     <i>",
"      E. coli",
"     </i>",
"     derived proteins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Dose-related bone marrow toxicity has been reported; use caution in patients with myelosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: The development of neurologic disorders have been noted at the higher doses; use with caution in patients with a history of seizure disorder or compromised CNS function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like symptoms: Have been noted at the higher doses and may exacerbate pre-existing cardiovascular disorders (including ischemia, HF, or arrhythmias).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May cause hepatotoxicity and the incidence may be increased in children &lt;1 year of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions/rash: Hypersensitivity reactions have been reported (rarely). Transient cutaneous rashes may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Investigational doses: Doses &gt;10 times the weekly recommended dose (used in studies for unlabeled indications) have been associated with a different pattern/frequency of adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F183618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. A dose-related abortifacient activity was reported in Rhesus monkeys. Safety and efficacy in pregnant women has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F183595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential for serious adverse reactions. Because its use has not been evaluated during lactation, breast-feeding is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Actimmune Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2000000 units/0.5 mL (0.5 mL): $1898.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelets, LFTs (monthly in children &lt;1 year), electrolytes, BUN, creatinine, and urinalysis prior to therapy and at 3-month intervals",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gama (CL);",
"     </li>",
"     <li>",
"      Immukin (HK);",
"     </li>",
"     <li>",
"      Immukine (BE, NL);",
"     </li>",
"     <li>",
"      Imufor (AR, AT);",
"     </li>",
"     <li>",
"      Imukin (AE, AT, AU, BH, CH, CO, CY, CZ, DE, DK, EG, ES, FI, FR, GB, GR, IL, IQ, IR, IT, JO, KW, LB, LY, NO, OM, PL, QA, SA, SE, SG, SY, TW, YE);",
"     </li>",
"     <li>",
"      Imukin Inj. (NZ);",
"     </li>",
"     <li>",
"      Intermax gamma (KP);",
"     </li>",
"     <li>",
"      Lizhu Yindefu (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4418991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferon gamma participates in immunoregulation by enhancing the oxidative metabolism of macrophages; it also enhances antibody dependent cellular cytotoxicity, activates natural killer cells and has a role in the expression of Fc receptors and histocompatibility antigens. The exact mechanism of action for the treatment of chronic granulomatous disease or osteopetrosis has not been defined.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F183592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M., SubQ: &gt;89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 38 minutes; I.M.: &sim;3 hours, SubQ: &sim;6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: I.M.: 4 hours (1.5 ng/mL); SubQ: 7 hours (0.6 ng/mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Key LL, Rodriguiz RM, Willi SM, et al,  &ldquo;Long-Term Treatment of Osteopetrosis With Recombinant Human Interferon Gamma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      1995, 332(24):1594-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20308/abstract-text/7753137/pubmed\" id=\"7753137\" target=\"_blank\">",
"        7753137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marciano BE, Wesley R, DeCarlo E, et al, &ldquo;Long-Term Interferon-Gamma Therapy for Patients With Chronic Granulomatous Disease,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(5):692-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20308/abstract-text/15356785/pubmed\" id=\"15356785\" target=\"_blank\">",
"        15356785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raghu G, Brown KK, Bradford WZ, et al, &ldquo;A Placebo-Controlled Trial of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004 Jan 8;350(2):125-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20308/abstract-text/14711911/pubmed\" id=\"14711911\" target=\"_blank\">",
"        14711911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8987 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20308=[""].join("\n");
var outline_f19_53_20308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183604\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183605\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183622\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183607\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183617\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183608\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962238\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962239\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934668\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183588\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183575\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4419053\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183589\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183620\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183593\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183578\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183618\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183582\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183584\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183594\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183613\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183595\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323199\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183586\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183596\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4418991\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183592\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8987|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/54/11109?source=related_link\">",
"      Interferon gamma-1b: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_53_20309="Lamivudine: Patient drug information";
var content_f19_53_20309=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lamivudine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     see \"Lamivudine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     see \"Lamivudine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epivir-HBV&reg;;",
"     </li>",
"     <li>",
"      Epivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      3TC&reg;;",
"     </li>",
"     <li>",
"      Apo-Lamivudine&reg;;",
"     </li>",
"     <li>",
"      Apo-Lamivudine&reg; HBV;",
"     </li>",
"     <li>",
"      Heptovir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis may get worse if this drug is stopped. Close watching is needed when therapy is stopped. HIV testing may be offered. Any HIV infection may be hard to treat after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691301",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during labor in women who have HIV but have not been treated.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hepatitis B infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lamivudine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for both hepatitis B and AIDS, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         HIV infection:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug changes for HIV infection, make sure to ask your doctor about hepatitis B care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705412",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Hepatitis B infection:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3432499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have never had hepatitis care before.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritated pancreas may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In HIV care, this drug is most often taken with 2 other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11774 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20309=[""].join("\n");
var outline_f19_53_20309=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186636\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186637\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020129\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020131\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020130\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020135\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020136\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020138\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020133\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020134\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020139\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020140\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=related_link\">",
"      Lamivudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=related_link\">",
"      Lamivudine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_53_20310="Giant cell arteritis inflam infiltrate";
var content_f19_53_20310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F83908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F83908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Inflammatory infiltrate in giant cell arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-power view of a superficial temporal artery involved by giant cell arteritis. Cell poor intimal thickness produces luminal narrowing (yellow arrow). The inflammatory infiltrate is most marked in the medial near the internal elastic lamina (black arrow). A small branch of the temporal artery is also involved (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gene G Hunder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20310=[""].join("\n");
var outline_f19_53_20310=null;
var title_f19_53_20311="Adalimumab: Pediatric drug information";
var content_f19_53_20311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Adalimumab: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"    see \"Adalimumab: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/61/3030?source=see_link\">",
"    see \"Adalimumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Humira&reg;;",
"     </li>",
"     <li>",
"      Humira&reg; Pen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humira&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F996315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antirheumatic, Disease Modifying",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Monoclonal Antibody",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Tumor Necrosis Factor (TNF) Blocking Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F996345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"      see \"Adalimumab: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Children and Adolescents &ge;4 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     15 kg to &lt;30 kg: 20 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;30 kg: 40 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Crohn's disease/ ulcerative colitis:",
"     </b>",
"     Children and Adolescents 9-18 years: Limited data available; dose not established; additional clinical trials ongoing; most experience with patients in whom infliximab tolerance develops (NCT00409682, 2011; Noe, 2008; Rosh, 2009; Viola 2009; Wyneski, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;40 kg:  80 mg on Week 0 followed by 40 mg on Week 2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &ge;40 kg:  160 mg on Week 0 followed by 80 mg on Week 2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose: Start on Week 4 (ie, 2 weeks after induction completed):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;40 kg: 20 mg every other week, if needed, dose may be increased by changing to weekly dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &ge;40 kg: 40 mg every other week; if needed, dose may be increased by changing to weekly dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Uveitis:",
"     </b>",
"     Children and Adolescents &gt;4 years: Limited data available; dose not established (Biester, 2007; Tynjala, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Body surface area-based dosing:  24 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (Simonini, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight-based dosing (Biester, 2007; Tynjala, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;30 kg: 20 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;30 kg: 40 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     40 mg every other week; may be administered with other DMARDs; patients not taking methotrexate may increase dose to 40 mg every week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Ankylosing spondylitis, psoriatic arthritis:",
"     </b>",
"     40 mg every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Crohn&rsquo;s disease:",
"     </b>",
"     Initial: 160 mg divided into 4 doses (ie, given as 4 injections on day 1 or as 2 injections per day over 2 consecutive days), then 80 mg 2 weeks later (day 15); maintenance: 40 mg every other week beginning day 29;",
"     <b>",
"      Note:",
"     </b>",
"     Some patients may require 40 mg every week as maintenance therapy (Lichtenstein, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Plaque psoriasis:",
"     </b>",
"     Initial: 80 mg as a single dose; maintenance: 40 mg every other week beginning 1 week after initial dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humira&reg;: 40 mg/0.8 mL (0.8 mL) [contains natural rubber/natural latex in packaging, polysorbate 80; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humira&reg; Pen: 40 mg/0.8 mL (0.8 mL) [contains natural rubber/natural latex in packaging, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humira&reg;: 20 mg/0.4 mL (0.4 mL) [contains natural rubber/natural latex in packaging, polysorbate 80; prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088611.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088611.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F996347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ injection; rotate injection sites. Do not use if solution is discolored. Do not administer to skin which is red, tender, bruised, or hard. To reduce pain of injection, some centers use 0.2 mL of 1% lidocaine and add adalimumab dose to the lidocaine syringe swirling gently to mix contents prior to administration (Ayala, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F996335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; protect from light; store in original carton until administration",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F996316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderately- to severely-active polyarticular juvenile idiopathic arthritis (JIA) alone or in combination with methotrexate (FDA approved in ages &ge;4 years); moderately- to severely-active rheumatoid arthritis (RA) alone or in combination with methotrexate or other nonbiologic, disease-modifying antirheumatic drugs (DMARDs) (FDA approved in adults); active psoriatic arthritis alone or in combination with nonbiologic DMARDs (FDA approved in adults); ankylosing spondylitis (FDA approved in adults); treatment of moderately- to severely-active Crohn&rsquo;s disease in patients with inadequate response to conventional treatment or patients who have lost response to or are intolerant of infliximab (FDA approved in adults); treatment of moderate to severe chromic plaque psoriasis (FDA approved in adults). Has also been used in children with idiopathic or JIA-associated uveitis, chronic uveitis, and for treatment of moderately- to severely-active Crohn&rsquo;s disease with inadequate response to conventional treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F130521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Humira&reg; may be confused with Humulin&reg;, Humalog&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Humira&reg; Pen may be confused with HumaPen&reg; Memoir&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F130519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, atrial fibrillation, chest pain, CHF, coronary artery disorder, deep vein thrombosis, heart arrest, hypertension, MI, palpitation, pericardial effusion, pericarditis, peripheral edema, syncope, tachycardia, vascular disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, fever, headache, hypertensive encephalopathy, multiple sclerosis, subdural hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cellulitis, erysipelas, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, hypercholesterolemia, hyperlipidemia, menstrual disorder, parathyroid disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diverticulitis, esophagitis, gastroenteritis, gastrointestinal hemorrhage, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis, pelvic pain, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, granulocytopenia, leukopenia, pancytopenia, paraproteinemia, polycythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, cholecystitis, cholelithiasis, hepatic necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, bone fracture, bone necrosis, CPK increased, joint disorder, muscle cramps, myasthenia, pain in extremity, paresthesia, pyogenic arthritis, synovitis, tendon disorder, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria, kidney calculus, pyelonephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion, pneumonia, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Accidental injury, adenoma, allergic reactions, antibodies to adalimumab (significance unknown), carcinoma (including breast, gastrointestinal, skin, urogenital), flu-like syndrome, healing abnormality, herpes zoster, hypersensitivity reactions (more common in children), ketosis, lupus erythematosus syndrome, lymphoma, melanoma, positive ANA, postsurgical infection, sepsis, serious infection (more common in adults), tuberculosis (reactivation of latent infection; miliary, lymphatic, peritoneal and pulmonary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abscess (limb, perianal), anal fistula, anaphylactoid reaction, anaphylaxis, angioedema, aplastic anemia, appendicitis, basal cell carcinoma, cerebrovascular accident, cervical dysplasia, circulatory collapse, cutaneous vasculitis, cytopenia, endometrial hyperplasia, erythema multiforme, fixed drug eruption, granuloma annulare (children and adolescents), Guillain-Barr&eacute; syndrome, HBV reactivation, hepatic failure, herpes virus infection, histoplasmosis, infections (bacterial, viral, fungal and protozoal), interstitial lung disease (eg, pulmonary fibrosis), intestinal obstruction, intestinal perforation, leukemias, liver metastases, lupus-like syndrome, lymphadenopathy, lymphocytosis, mycobacterium avium complex infection, myositis (children and adolescents), necrotizing fasciitis, neutropenia, optic neuritis, ovarian cancer, pancreatitis, pharyngitis (children and adolescents), psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pulmonary embolism, respiratory failure, sarcoidosis, septic arthritis, septic shock, skin ulceration, Stevens-Johnson syndrome, streptococcal pharyngitis (children and adolescents), systemic vasculitis, testicular cancer, thrombocytopenia, transaminases increased, viral meningitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F996321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to adalimumab or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9525790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing or recent onset central or peripheral nervous system demyelinating disorders; rare cases of new-onset or exacerbation of demyelinating disorders (eg, multiple sclerosis, Guillain-Barre syndrome) have been reported; consider discontinuing use in patients who develop peripheral or central nervous system demyelinating disorders during treatment. Rare cases of pancytopenia (including aplastic anemia) have been reported with TNF-blocking agents; if significant hematologic abnormalities occur, consider discontinuing therapy. Caution should be exercised in patients with congestive heart failure (CHF) or decreased left ventricular function; worsening or new onset CHF have been reported with TNF blockers. Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There are no data available concerning secondary transmission of infection from live vaccine in patients receiving adalimumab. Positive antinuclear antibody titers have been detected in patients (with negative baselines); rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop. The needle cover of syringe contains latex; patients with latex allergy should avoid contact.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F996322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and potentially fatal infections have been reported with use",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; reported infections include tuberculosis (TB), bacterial sepsis,",
"     <i>",
"      Listeria",
"     </i>",
"     and",
"     <i>",
"      Legionella",
"     </i>",
"     infection, invasive fungal infections, and infections due to other opportunistic pathogens (eg, mycobacterial infection, pneumocystosis). Adalimumab should be discontinued if a patient develops a serious infection or sepsis during treatment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Caution should be exercised when considering the use in patients with chronic infection, history of recurrent infection, or predisposition to infection. In patients receiving TNF-blocking agents, other commonly reported opportunist pathogens include aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis. Patients frequently present with disseminated disease rather than localized and concomitant immunosuppressive therapy (eg, methotrexate or corticosteroids) is often present. Do not initiate therapy in patients who have the following: An active chronic or localized infection, been exposed to tuberculosis,  a history of an opportunistic infection, lived in or traveled to areas where tuberculosis or mycoses are endemic, or predisposing underlying conditions. Avoid concomitant use with anakinra (interleukin-1 antagonist) or abatacept; serious infections have been reported with other TNF-blockers (etanercept) when used with anakinra and abatacept.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tuberculosis, both reactivation and new infection, has been reported in patients receiving adalimumab; most cases have been reported within the first 8 months of treatment; higher than recommended doses of adalimumab are associated with increased risk for reactivation. Perform test for latent TB before use; if positive (induration &gt;5 mm, regardless if previously vaccinated with BCG), initiate  treatment for latent TB prior to starting adalimumab",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; consider antituberculosis treatment for patients with history of latent or active TB in which complete course of therapy cannot be confirmed or those with risk factors for TB despite testing negative for latent TB. Monitor all patients for active TB during treatment, even if initial latent TB test is negative",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ,  particularly those with close contact to a person with active TB or recent travel to an endemic area.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In children and adolescents, lymphomas and other malignancies, some fatal, have been reported with use of TNF blockers",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; postmarketing reports were primarily in patients with Crohn&rsquo;s disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly  in adolescent and young adult males. Use of adalimumab may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. In an analysis of children and adolescents who had received TNF blockers (etanercept and infliximab), the FDA identified 48 cases of malignancy. Of the 48 cases, ~50% were lymphomas (eg, Hodgkin&rsquo;s and non-Hodgkin&rsquo;s lymphoma). Other malignancies such as leukemia, melanoma, and solid organ tumors were reported; malignancies rarely seen in children (eg, leiomyosarcoma, hepatic malignancies, and renal cell carcinoma) were also observed. Of note, most of these cases (88%) were receiving other immunosuppressive medications (eg, azathioprine and methotrexate). A higher incidence of nonmelanoma skin cancers was noted in adalimumab-treated adults (0.7/100 patient years), when compared to the control group (0.2/100 patient years). As compared to the general population, an increased risk of lymphoma has been noted in adult clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma. The role of TNF blockers in the development of malignancies in children cannot be excluded. The FDA also reviewed 147 postmarketing reports of leukemia (including acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) in patients (children and adults) using TNF blockers. Average onset time to development of leukemia was within the first 1-2 years of TNF blocker initiation. Although most patients were receiving other immunosuppressive agents, the role of TNF blockers in the development of leukemia could not be excluded. The FDA concluded that there is a possible association with the development of leukemia and the use of TNF blockers. Patients should be monitored closely for signs and symptoms suggestive of malignancy, evidence of which should result in prompt discontinuation of the medication and appropriate diagnostic evaluation. Healthcare professionals should report any malignancies in patients (particularly those &lt;0 years of age) being treated with TNF blockers to the FDA's MedWatch program.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May also cause new-onset psoriasis. Analysis by the FDA identified 69 cases of new-onset psoriasis (including pustular, palmoplantar) occurring in patients using TNF blockers for the treatment of conditions other than psoriasis and psoriatic arthritis. Of the 69 cases, two were reported in children and 12 required hospitalization, the most severe outcome. Improvement was seen when the TNF blocker was discontinued. The FDA concluded that there is a possible association with new-onset psoriasis and the use of TNF blockers. Patients should be monitored closely for signs and symptoms suggestive of new-onset psoriasis, evidence of which should result in prompt discontinuation of the medication and appropriate diagnostic evaluation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May rarely cause hypersensitivity reactions; reported incidence during adult clinical trials: 1%; anaphylaxis and angioneurotic edema have been reported. Therapy should be immediately discontinued and appropriate therapy initiated if anaphylactic or other serious allergic reaction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rare reactivation of hepatitis B virus (HBV) has occurred in chronic HBV carriers; evaluate prior to initiation, during, and for several months after treatment. Determine status of patients at risk for HBV infection prior starting therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Adalimumab may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Adalimumab may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Adalimumab may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies, however, there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. A pregnancy registry has been established to monitor outcomes of women exposed to adalimumab during pregnancy (877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F996349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Place and read PPD before initiation and periodically during therapy. Monitor improvement of symptoms and physical function assessments; CBC; signs of infection, bleeding, or bruising; signs of HBV reactivation in patients who are carriers (during therapy and several months following discontinuation)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F996337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adalimumab binds to TNF-alpha and blocks its interaction with cell surface TNF receptors rendering TNF biologically inactive; modulates biological responses that are induced or regulated by TNF.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F996339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4.7-6 L; synovial fluid concentrations: 31% to 96% of serum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: ~2 weeks (range: 10-20 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ: 131 &plusmn; 56 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance increased in the presence of antiadalimumab antibodies; decreased in patients &ge;40 years",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F996352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/61/3030?source=see_link\">",
"      see \"Adalimumab: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause headache, nausea, or stomach pain. Notify prescriber of any signs of infection. If self-administered, follow directions for injection and needle/syringe disposal exactly. You may be more susceptible to infection. Do not have any vaccinations while using this medication without consulting prescriber first. Report persistent fever, increased bruising or bleeding, respiratory tract infection, unhealed or infected wounds, urinary tract infection, flu-like symptoms, unexplained weight loss, persistent cough, or unusual bump or sore that does not heal. Stop drug and report immediately persistent nausea, abdominal pain; numbness or tingling; problems with vision; weakness in legs; chest pains, respiratory difficulty; sudden weight gain of &gt;3-5 pounds/week; swelling of extremities; joint pain; skin rash; redness, swelling, or pain at injection site.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F9525795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pregnancy registry has been established to monitor outcomes of women exposed to adalimumab during pregnancy (877-311-8972).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ayala RS, Groh BP, Robbins LM, et al, \"The Addition of Injectable Lidocaine to Adalimumab Results in Decreased Injection Site Pain and Increased Acceptance of Therapy,\" 2008, American College of Rheumatology Annual Scientific Meeting, San Francisco, CA (poster).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beukelman T, Patkar NM, Saag KG, et al, \"2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features,\"",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2011, 63(4):465-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/21452260/pubmed\" id=\"21452260\" target=\"_blank\">",
"        21452260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biester S, Deuter C, Michels H, et al, \"Adalimumab in the Therapy of Uveitis in Childhood,\"",
"      <i>",
"       Br J Ophthalmol",
"      </i>",
"      , 2007, 91(3):319-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/17035274/pubmed\" id=\"17035274\" target=\"_blank\">",
"        17035274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furst DE, Keystone EC, Kirkham B, et al, \"Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2008,\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2008, 67 Suppl 3:iii2-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/19022808 /pubmed\" id=\"19022808 \" target=\"_blank\">",
"        19022808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, \"Management of Crohn's Disease in Adults,\"",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lovell DJ, Ruperto N, Goodman S, et al, \"Adalimumab With or Without Methotrexate in Juvenile Rheumatoid Arthritis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(8):810-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/18716298/pubmed\" id=\"18716298\" target=\"_blank\">",
"        18716298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noe JD and Pfefferkorn M, \"Short-Term Response to Adalimumab in Childhood Inflammatory Bowel Disease,\"",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2008, 14(12):1683-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/18618629/pubmed\" id=\"18618629\" target=\"_blank\">",
"        18618629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosh JR, Lerer T, Markowitz J, et al, \"Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease,\"",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(12):3042-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/19724267/pubmed\" id=\"19724267\" target=\"_blank\">",
"        19724267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simonini G, Taddio A, Cattalini M, et al, \"Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: An Open-Label Comparative Study of Adalimumab Versus Infliximab,\"",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2011, 63(4):612-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/21452272/pubmed\" id=\"21452272\" target=\"_blank\">",
"        21452272",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tynj&auml;l&auml; P, Kotaniemi K, Lindahl P, et al, \"Adalimumab in Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis,\"",
"      <i>",
"       Rheumatology (Oxford)",
"      </i>",
"      , 2008, 47(3):339-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/18238789/pubmed\" id=\"18238789\" target=\"_blank\">",
"        18238789",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viola F, Civitelli F, Di Nardo G, et al, \"Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease,\"",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(10):2566-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/19550415/pubmed\" id=\"19550415\" target=\"_blank\">",
"        19550415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyneski MJ, Green A, Kay M, et al, \"Safety and Efficacy of Adalimumab in Pediatric Patients With Crohn Disease,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2008, 47(1):19-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20311/abstract-text/18607264/pubmed\" id=\"18607264\" target=\"_blank\">",
"        18607264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13077 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20311=[""].join("\n");
var outline_f19_53_20311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708607\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130499\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855045\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996315\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996345\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130481\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130468\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874545\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996347\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996335\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996316\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130521\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130519\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996321\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9525790\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996322\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298685\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130475\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130477\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130488\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996349\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996337\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996339\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996352\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9525795\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13077\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13077|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=related_link\">",
"      Adalimumab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/61/3030?source=related_link\">",
"      Adalimumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_53_20312="Planned home birth";
var content_f19_53_20312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Planned home birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/53/20312/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/53/20312/contributors\">",
"     Eugene Declercq, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/53/20312/contributors\">",
"     Naomi E Stotland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/53/20312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/53/20312/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/53/20312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/53/20312/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/53/20312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planned home birth is a subject of ongoing controversy. The American College of Obstetricians and Gynecologists' (ACOG) Committee on Obstetric Practice states that hospitals and birthing centers are the safest setting for birth, but they respect the right of women to make medically informed decisions about their delivery site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/1\">",
"     1",
"    </a>",
"    ]. The American College of Nurse Midwives [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/2\">",
"     2",
"    </a>",
"    ] and the American Public Health Association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/3\">",
"     3",
"    </a>",
"    ] have policy statements supporting the practice of planned out-of-hospital birth in select populations of women. The World Health Organization (WHO) has released a statement indicating women can choose to deliver at home if they have low-risk pregnancies, receive the appropriate level of care, and formulate contingency plans for transfer to a",
"    <span class=\"nowrap\">",
"     properly-staffed/equipped",
"    </span>",
"    delivery unit if problems arise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/4\">",
"     4",
"    </a>",
"    ]. In the Dutch system, pregnant women without medical complications are asked to choose where they want to give birth: at home or in a short-stay hospital setting. The home birth rate in the Netherlands is the highest in the developed world, although it has declined from 35 percent of all births in 1997-2000 to 29 percent of all births in 2005-2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss planned home birth. Delivery at birth centers and unplanned home birth are reviewed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25048?source=see_link\">",
"       \"Birth centers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/1/5141?source=see_link\">",
"       \"Precipitous birth not occurring on a labor and delivery unit\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNITED STATES NATALITY DATA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence of home birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States National Center for Health Statistics reports birth data based on state vital statistics records, which are determined from the Standard Certificate of a Live Birth (ie, birth certificate). Prior to 1989, births were identified as either occurring in or out of a hospital (eg, home, car, office). Since 1989, a specific category for home births was included on the Standard Certificate. Since 2003, some states have changed their Standard Certificate to identify planned versus unplanned home births and, by 2008, there were 27 states which reported planning status, accounting for 68 percent of all home births.",
"   </p>",
"   <p>",
"    In 2009 (the most recent complete figures available), there were 44,121 out-of-hospital births in the United States: 29,650 were home births and 12,169 occurred in free standing birthing centers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/6\">",
"     6",
"    </a>",
"    ]. Thirteen percent of the home births were unplanned in 2008 (range 1 to 33 percent among the 27 states reporting these data). From 1989 to 2003, the overall rate of home births in the United States declined from 0.69 to 0.57 percent of births, or by an average of 0.01 percent annually. The 2009 figures represent a substantial increase in both absolute numbers and rate, reaching 0.72 percent of all births, the highest United States home birth rate since 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Almost all of the increase was attributed to births among non-Hispanic white women.",
"   </p>",
"   <p>",
"    This rate is comparable to that in other industrialized countries with two exceptions: England has experienced a slight rise in its home birth rate from 1.0 percent in 1989 to 2.9 percent in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/10\">",
"     10",
"    </a>",
"    ], while the Netherlands has maintained rates of home birth of approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, 10 states had home birth rates at least double the United States national average, including: Montana (2.2 percent), Vermont (2.0 percent), Alaska (1.6 percent), Idaho (1.5 percent), and Utah (1.4 percent). These states are predominantly rural; however, some nonrural states also have relatively high rates of home birth: Oregon (1.9 percent), Wisconsin (1.6 percent), Pennsylvania (1.5 percent), and Washington (1.5 percent). In Wisconsin, the home births were disproportionately located in rural counties. In Pennsylvania, the high rate of home birth was due, at least in part, to a large Amish population, which has traditionally relied on home birth. Lancaster County, for example, had the highest home birth rate of any county in the United States: 12.9 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Birth attendant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of home births in the United States provided by different types of birth attendants is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef59460 \" href=\"UTD.htm?33/27/34236\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/12\">",
"     12",
"    </a>",
"    ]. The qualifications of the different types of midwives are described below (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Provider'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Physicians and certified nurse midwives (the two dominant birth attendants for hospital births) attend fewer than 25 percent of home births, with \"other midwives\" (primarily certified professional midwives) attending 44 percent and \"other\" attendants attending 32 percent. The \"other\" category is a residual category for attendants (eg, fathers) not meeting the criteria for the categories provided. In some cases, fathers may sign the birth certificate to protect birth attendants (eg, direct entry midwives) in states with legal restrictions on planned home birth or type of provider for home birth. In other cases, the woman has planned an unassisted birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of birth attendant varies widely by",
"    <span class=\"nowrap\">",
"     race/ethnicity.",
"    </span>",
"    Black non-Hispanic mothers were usually attended by either \"other\" (56 percent) or a physician (20 percent), while white non-Hispanic mothers were primarily attended by other midwives (47 percent) or \"other\" (28 percent). Hispanic mothers relied on \"other\" (39 percent) and other midwives (39 percent). The higher rate of physician attendance at home births for black non-Hispanic mothers is, in part, a reflection of the higher rate of unplanned home births among these mothers combined with the higher rate of physician attendance at unplanned home births. When physicians were recorded as home birth attendants, it was usually (69 percent) an unplanned home birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WOMEN WHO CHOOSE HOME BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little systematic research has been performed on the motivation of United States mothers who plan home birth; most studies report survey data from select groups of women. These women tend to be self-reliant, more comfortable with their own intuition than with professional advice, adverse to medical intervention and technology, confident about the normality of childbirth, and they have a belief in their bodies' inherent ability to give birth without interference [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Demographics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table shows demographic data of mothers who gave birth at home (planned and unplanned) in the United States in 2009 (",
"    <a class=\"graphic graphic_table graphicRef78648 \" href=\"UTD.htm?16/18/16684\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/17\">",
"     17",
"    </a>",
"    ]. Approximately one out of every 140 births in the United States overall was a home birth, while for non-Hispanic white women, approximately one out of every 90 births was a home birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition to being predominantly white non-Hispanic, women who had home births were more likely to be older, multiparous, native born, living in a nonmetropolitan county, and nonsmokers. They were much more likely to report not having had prenatal care than women who delivered in a hospital. Educational levels were comparable for women who gave birth at home and those who delivered in a hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reasons for choosing home birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have identified many different reasons women choose to give birth at home, including [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/16,19-24\">",
"     16,19-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A desire for a low-intervention birth, in particular the avoidance of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      , epidural analgesia, pharmacologic pain relief, episiotomy, instrumental vaginal delivery, and cesarean birth",
"     </li>",
"     <li>",
"      Cultural or religious concerns (eg, the Amish, religions that proscribe male birth attendants)",
"     </li>",
"     <li>",
"      A concern about iatrogenic complications of hospital birth; fear of and dissatisfaction with hospital care",
"     </li>",
"     <li>",
"      A desire for freedom and control in the birth process",
"     </li>",
"     <li>",
"      A desire to give birth in a comfortable, familiar environment surrounded by family and friends",
"     </li>",
"     <li>",
"      Lack of access to transportation (rural areas)",
"     </li>",
"     <li>",
"      Economic concerns",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OUTCOMES OF HOME BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have reported the maternal and neonatal outcomes of home birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/25-38\">",
"     25-38",
"    </a>",
"    ]. Generally these studies have found that, compared to planned hospital birth, planned home birth is associated with reduced rates of cesarean birth and medical interventions, and similar rates of maternal and perinatal morbidity and mortality. However, there are significant limitations to the quality of population data available for systematic analysis and, in some cases, on the methodological quality of the studies themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Limitations of available data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of birth certificate data to assess outcomes of home birth limits interpretation of findings because birth certificates prior to 2003 did not distinguish between planned and unplanned home births or cases where a home birth resulted in a transfer to a hospital. These omissions created biases in opposite directions. The failure to identify planned home births meant a portion of the home births were the result of emergencies, perhaps involving precipitous labor, which might result in a poorer than average outcome when occurring in a setting unprepared for a delivery. Such cases are not uncommon. As noted above, 2007 birth certificate data from 21 United States states revealed that 14 percent of recorded home births were unplanned. In contrast, not accounting for hospital transfers meant those planned home births with potentially the worst outcomes were counted as hospital births. These issues were partially addressed in 2003 when birth certificates were changed to identify planned versus unplanned home births, but states have been slow to adopt the new certificate (as of 2007, 56 percent of birth certificates included planning status of home birth).",
"   </p>",
"   <p>",
"    Several reviews have attempted to summarize studies on the perinatal and maternal outcomes associated with home births. Such studies are very difficult to compare because of the lack of data on planning status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfers to hospitals, use of different outcome measures (eg, neonatal or perinatal death rates), alternative approaches to classification of deaths associated with congenital anomalies, and lack of a similar population of appropriately screened hospital births to use as controls. Confounders that affect comparisons of reported outcomes include differences in: the",
"    <span class=\"nowrap\">",
"     medical/obstetrical",
"    </span>",
"    risk status of the parturients, parity (nulliparous versus parous), competence of birth attendants, and birth practices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/15\">",
"     15",
"    </a>",
"    ]. As an example, a study from Southern Australia found that home birth was associated with a significantly higher rate of intrapartum death from asphyxia than hospital birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/37\">",
"     37",
"    </a>",
"    ]. Review of the perinatal deaths in the planned home birth group identified inappropriate inclusion of women with risk factors for home birth and inadequate fetal surveillance during labor, which highlights the importance of assessing patient and provider factors in home birth outcome.",
"   </p>",
"   <p>",
"    Many of the higher quality studies have been from industrialized countries other than the United States. These countries can have approaches to maternity care very different from that in the United States, and often have much more integrated support systems for",
"    <span class=\"nowrap\">",
"     women/infants",
"    </span>",
"    who must be transferred from the home setting to the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Evidence",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553115807\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 12 English-language peer reviewed publications from developed Western nations evaluated maternal and newborn outcomes associated with planned home or planned hospital birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/40\">",
"     40",
"    </a>",
"    ]. The challenges in systematically studying home birth outcomes are illustrated by this analysis. It was dominated by a retrospective population-based cohort study from the Netherlands with more than one half million women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/29\">",
"     29",
"    </a>",
"    ], but also included a failed attempt at a randomized trial that involved only 11 women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/41\">",
"     41",
"    </a>",
"    ] and several prospective studies ranging in size from 200 to more than 1000 women. Only two studies from the United States met the inclusion criteria: one involved data from 1976 to 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/42\">",
"     42",
"    </a>",
"    ] and the other relied on birth certificate data that could only infer planning status [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/25\">",
"     25",
"    </a>",
"    ]. The largest United States study that has been performed (described below [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/31\">",
"     31",
"    </a>",
"    ]) was excluded because it did not include a linked comparison group of low risk hospital births. Subsequent analyses have raised further methodological questions concerning this meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this meta-analysis, planned home birth was associated with significant reductions in intrapartum interventions (epidural anesthesia, electronic fetal heart rate monitoring, episiotomy, operative vaginal delivery, cesarean deliver); odds ratios ranged from 0.1 to 0.42. Planned home birth was also associated with significant reductions in maternal morbidity (3rd degree laceration, infection, postpartum bleeding, perineal laceration, vaginal laceration, retained placenta); odds ratios ranged from 0.27 to 0.85. There were no maternal deaths.",
"   </p>",
"   <p>",
"    Perinatal mortality, which encompasses both fetal deaths and early (up to seven days) neonatal deaths, was similar for both planned home births and planned hospital births. The meta-analysis authors chose to exclude the Dutch study from their analysis of neonatal death because this study only examined early neonatal death, rather than the 28-day standard they chose for the meta-analysis. The Dutch study found no difference between groups in deaths up to seven days; however, when these data were excluded, neonatal death up to 28 days was significantly higher in the planned home birth group: all neonatal deaths OR 1.98 (95% CI 1.19-3.28) and nonanomalous neonatal deaths OR 2.87 (95% CI 1.32-6.25).",
"   </p>",
"   <p>",
"    The authors could not determine the reason for the two- to three-fold higher 28 day neonatal death rate in planned home births. They hypothesized that it might be due to less maternal intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a higher risk of respiratory distress and failed neonatal resuscitation in the planned home delivery group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Prospective studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings illustrate data from two large prospective studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest contemporary prospective study of home births in the United States and Canada involved 5418 women who utilized a certified professional midwife as their primary caregiver and planned to deliver at home [",
"      <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/31\">",
"       31",
"      </a>",
"      ]. Women who became high risk intrapartum were transferred to the hospital. Major findings were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rates of medical intervention for home births were consistently less than half those for hospital births, whether compared with a relatively low risk group or the general obstetric population of hospital births. For the planned home and planned hospital birth groups, the episiotomy rate was 2.1 versus 33.0 percent in hospital, the cesarean delivery rate was 3.7 versus 19.0 percent in hospital, the rate of forceps delivery was 1.0 versus 2.2 percent in hospital, the induction rate was 9.6 versus 21 percent in hospital, and the electronic fetal monitoring rate was 9.6 versus 84.3 percent in hospital.",
"      <br/>",
"      <br/>",
"      However, it is difficult, if not impossible, to match planned home birth patients to planned hospital birth patients since both groups are self-selected. In particular, the home birth population tends to be healthy, multiparous, of above average education and means, and adverse to intervention.",
"     </li>",
"     <li>",
"      12.1 percent of patients were transferred to a hospital intrapartum or postpartum. Five out of every six women transferred (83.4 percent) were transferred before delivery, half of these transfers were for failure to progress, pain relief, or exhaustion. After delivery, 1.3 percent of mothers and 0.7 percent of newborns were transferred to a hospital, usually because of maternal hemorrhage (0.6 percent of births), retained placenta (0.5 percent of births), or newborn respiratory problems (0.6 percent of births).",
"     </li>",
"     <li>",
"      There were no maternal deaths.",
"     </li>",
"     <li>",
"      Intrapartum and neonatal mortality in pregnancies at low risk at start of labor, excluding deaths from life threatening congenital anomalies, was 1.7 deaths per 1000 planned home births, which was similar to the rate in other studies of low risk home and hospital births in North America. In the planned home birth group, there were five intrapartum fetal deaths (one cord prolapse, two breech presentations, one intracranial hemorrhage, one true knot with six nuchal cords), seven infant deaths in the week after birth",
"      <span class=\"nowrap\">",
"       (3/7",
"      </span>",
"      were related to lethal congenital anomalies), and two other infant deaths within 28 days of birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subsequent prospective cohort study of home births in Canada also reported maternal and neonatal outcomes in planned home births were similar to, or lower than, rates in planned hospital births [",
"      <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/33\">",
"       33",
"      </a>",
"      ]. Strengths of this study were that the same midwives performed both in hospital and home births, the planned hospital birth group was limited to women who met eligibility criteria for planned home birth, and high ascertainment of outcome data. Specific findings were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rates of perinatal death for the planned home birth and planned hospital birth were 0.35 and 0.57 per 1000 births, respectively (perinatal death defined as stillbirth after 20 weeks of gestation or death in the first seven days of life).",
"     </li>",
"     <li>",
"      Women in the planned home birth group were significantly less likely than women in the planned midwife-attended hospital birth group to have obstetric interventions or adverse maternal outcomes (third- or fourth-degree perineal tear, postpartum hemorrhage).",
"     </li>",
"     <li>",
"      Newborns in the home birth group were significantly less likely than those in the midwife attended hospital birth group to require resuscitation at birth or oxygen therapy beyond 24 hours and they were less likely to have meconium aspiration.",
"      <br/>",
"      <br/>",
"      Since the same group of midwives attended the home births and the hospital births, the differences in newborn outcomes are unlikely to be related to differences in skills or management of newborn resuscitation. It is possible that hospital protocols about newborn resuscitation and use of oxygen may explain some of these differences. It is also possible that the lack of pharmacologic pain relief and lack of labor augmentation in home births explain the lower need for newborn resuscitation, but there is no information in the article to support or refute this.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large prospective study, &ldquo;Birthplace in England,&rdquo; compared the outcomes of low risk mothers planning to deliver at an alternative birth site (home, freestanding midwifery units, midwifery run units within hospitals) to those of a comparable population planning to deliver in obstetrical units throughout England [",
"      <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. The final sample consisted of 64,538 women with singleton, term births from 2008 to 2010. The primary composite outcome consisted of stillbirth after the start of labor, early neonatal death, neonatal encephalopathy, meconium aspiration syndrome, brachial plexus injury, and fractured humerus or clavicle. Mortality alone was too rare for useful statistical analysis. Major findings were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There were only 250 primary adverse outcome events, giving an overall weighted incidence of 4.3 per 1000 births in this low-risk population.",
"     </li>",
"     <li>",
"      Overall, the odds (adjusted) of the composite outcome were similar for the three alternative birth settings and the obstetrical units.",
"     </li>",
"     <li>",
"      When analyzed by parity, first time mothers planning to deliver at an alternative birth setting were significantly more likely to experience transfer to hospital than multiparous mothers (44 versus 9.2 percent).",
"     </li>",
"     <li>",
"      First time mothers planning to deliver in an alternative birth setting had a significantly higher occurrence of the composite outcome (0.93 percent) than first time mothers planning to deliver in an obstetrical unit (0.53 percent), even after adjustment for maternal characteristics. In multiparous women, there was no significant difference in the odds of the composite outcome between planned alternative setting and planned hospital births.",
"     </li>",
"     <li>",
"      The rates of cesarean delivery, augmentation of labor, and epidural anesthesia were significantly lower in planned alternative setting births than in births planned for obstetrical units: intrapartum cesarean delivery (2.8 percent versus 11.1 percent); augmentation (5.4 versus 23.5 percent); epidural anesthesia (8.3 percent versus 30.7 percent).",
"     </li>",
"     <li>",
"      For low risk pregnancies, planned home birth is more cost-effective than other birth settings.",
"      <br/>",
"      <br/>",
"      By analyzing data according to parity, this study provides an important new insight about the risk of home birth. Although planned home births have fewer interventions, for nulliparous women, these births are associated with poorer perinatal outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14539050\">",
"    <span class=\"h3\">",
"     Retrospective studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies comparing the outcomes of women who planned home birth to matched women who planned hospital births have generally found that intrapartum and early neonatal mortality rates for the planned home birth group were as low as, or lower than, those in the hospital group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/26,28,29,34-36,38,47\">",
"     26,28,29,34-36,38,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home birth can be a viable option for carefully screened low risk mothers with good labor support and a back-up plan to facilitate transfer, if needed. While other countries have developed such integrated plans for care, few such examples exist in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26869395\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women considering planned home birth should be informed of its risks and benefits based on the meta-analysis discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/40\">",
"     40",
"    </a>",
"    ] that planned home birth appears to be associated with a two-fold to three-fold increased risk of late neonatal death when compared with planned hospital birth, although the absolute risk may be low [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/1\">",
"     1",
"    </a>",
"    ]. The provider&rsquo;s ethical obligations regarding discussing home birth with patients have been the subject of commentaries elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Provider",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, access to quality out-of-hospital birth services varies greatly by geographic locale. Most home births are attended by midwives, although a few physicians are also willing to attend home births. There are three different categories of midwife, which vary by the amount of training, oversight and credentialing they receive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct-entry midwife (DEM): a health care professional who may or may not have a college degree or certification. Direct-entry midwives train through some combination of apprenticeship, workshops, and formal instruction. DEMs usually practice in homes or freestanding birth centers. The legal status of DEMs varies from state to state.",
"     </li>",
"     <li>",
"      Certified nurse-midwife (CNM): a health care professional who has received a degree as a registered nurse (RN) followed by additional graduate-level training in pregnancy and birth. CNMs work in collaboration with physicians.",
"     </li>",
"     <li>",
"      Certified professional midwife (CPM): a health care professional certified by the North American Registry of Midwives after passing written exams, as well as hands-on skill evaluations. Both direct-entry midwives and certified nurse-midwives can apply for this certification. CPMs are required to have out-of-hospital birth experience, and usually practice in homes and birth centers. Their legal status varies according to state with 25 states recognizing them in some form (licensure, certification, registration) as of May, 2010.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no consensus on what constitutes the optimal qualifications for a home birth attendant in the United States. Women may find assistance in seeking a qualified provider by contacting one of the following organizations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      American College of Nurse-Midwives:",
"      <a class=\"external\" href=\"file://www.midwife.org/\">",
"       www.midwife.org",
"      </a>",
"     </li>",
"     <li>",
"      Midwives Alliance of North America:",
"      <a class=\"external\" href=\"file://www.mana.org/\">",
"       www.mana.org",
"      </a>",
"     </li>",
"     <li>",
"      Childbirth Connection:",
"      <a class=\"external\" href=\"file://www.childbirthconnection.org\">",
"       www.childbirthconnection.org",
"      </a>",
"     </li>",
"     <li>",
"      DONA International:",
"      <a class=\"external\" href=\"file://www.dona.org/\">",
"       www.dona.org",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable controversy over the specific patient characteristics and risks that might compromise the safety of out-of-hospital birth. Many countries have established such lists based on expert panel recommendations, as well as local and international outcomes data [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/50\">",
"     50",
"    </a>",
"    ], but no such list exists for the United States. While determining the appropriate birth setting ultimately falls upon the woman and her birth provider, women who may be good candidates for an out-of-hospital birth include the following (this should not be considered a complete list):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A woman who has chosen home birth on the basis of informed consent",
"     </li>",
"     <li>",
"      Singleton, cephalic fetus at term",
"     </li>",
"     <li>",
"      Absence of preexisting serious medical conditions (eg, cardiac, renal disease, coagulopathy, diabetes mellitus managed with insulin)",
"     </li>",
"     <li>",
"      Absence of serious obstetrical conditions (eg, preeclampsia, antepartum bleeding)",
"     </li>",
"     <li>",
"      No prior cesarean deliveries",
"     </li>",
"     <li>",
"      Absence of contraindications to vaginal birth (eg, placenta previa, active genital herpes)",
"     </li>",
"     <li>",
"      Spontaneous labor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some guidelines also include women with one prior low transverse cesarean delivery or who are being induced [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2720169\">",
"    <span class=\"h2\">",
"     Group B streptococcus and home birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS) screening and&nbsp;intrapartum antibiotic prophylaxis&nbsp;for women planning home birth is controversial. Based on their training, certification, and local regulations, some home birth providers are able to administer intravenous antibiotics when indicated according to the Centers for Disease Control and Prevention (CDC) guidelines for GBS-positive women. When intrapartum intravenous antibiotic prophylaxis is not technically possible, home birth providers have proposed a variety of alternatives; however, the effectiveness of these approaches is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Organization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Dutch system is probably the best model of planned home birth for an industrialized country, given the large number of successful home births in the Netherlands. The continued high rate of home births in the Netherlands is unique among industrialized countries and is a legacy of a strong reliance on independent direct entry midwives, a widespread view among families that birth is a natural process, a generalized questioning of the use of technological interventions in medicine, a view of obstetricians as specialists in high risk births only, and a pride in the uniqueness of their status as center for home birth in the industrialized world [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/11\">",
"     11",
"    </a>",
"    ]. This system has several important features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A highly organized system of midwifery care. Dutch midwives are trained in a four-year program that prepares them to practice in the hospital or in the home and to recognize and manage some pregnancy complications. Early pregnancy care is primarily delivered by independently practicing midwives. If complications occur or threaten to occur, the midwife refers the woman to an obstetrician at the secondary or tertiary care level. At that point, the woman is no longer eligible for home birth.",
"     </li>",
"     <li>",
"      Formal agreements for collaboration between professional groups that have been specified in the Verloskundig Vademecum (Obstetric Manual), which also includes a list of obstetric indications for referral from primary to secondary care, based on best evidence or consensus. This provides a clear distinction between women at low risk and those at high risk of problems during pregnancy, labor, and delivery.",
"     </li>",
"     <li>",
"      A timely transfer system where the average distance to the hospital is relatively short. In Amsterdam, 85 percent of urgent obstetric referrals arrived in the hospital within half an hour. In addition, the midwife is able to provide some interventions herself in the woman's home, such as the administration of an intravenous infusion and provision of basic life support.",
"     </li>",
"     <li>",
"      Lack of intervention, eg, pharmacologic methods of pain relief are not offered to women laboring at home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Periodic measurement of temperature, pulse, blood pressure, and fetal heart rate is part of the ongoing assessment of labor, not interventions, and should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/4\">",
"     4",
"    </a>",
"    ]. A clean delivery kit should be available. Instruments that come into contact with mucous membranes or non-intact skin, or penetrate the skin or mucous membranes, should be sterile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Newborn care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standards for newborn care in the home birth setting should be consistent with state and federal regulations. For example, administration of vitamin K and eye prophylaxis and metabolic screening should be explained and offered, but parents have a right to refuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hospital transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seven to 20.4 percent of women attempting out-of-hospital birth will be transferred to the hospital either intrapartum or postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/28,44\">",
"     28,44",
"    </a>",
"    ]. As discussed above, the largest prospective study of United States home births reported 12.1 percent of cases required transfer, and about 25 percent of these were classified as urgent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, the back-up hospital should provide 24-hour maternity care and should be within 15 minutes of the home, but this may not be possible, especially in some geographic areas where home birth is more common precisely because of the lack of nearby hospitals. In such settings, home birth providers should have a lower threshold for transferring patients to the hospital and must consider the transfer time when caring for patients in labor. Women delivering in homes that are remote from a hospital should be informed by their home birth provider during prenatal care that in the case of an unforeseen catastrophic complication (eg, abruption, cord prolapse), they may not be able to transfer to the hospital in time to avoid maternal or neonatal injury or death.",
"   </p>",
"   <p>",
"    An optimum outcome is facilitated when hospital providers, including nurses, physicians, and hospital-based midwives, communicate in a respectful manner with home birth providers and their clients during the transfer process. Home birth providers and their clients sometimes report that they are treated \"punitively\" or disrespectfully by hospital staff when a transfer occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/19,53\">",
"     19,53",
"    </a>",
"    ]. This perception may lead to a delay in a needed transfer, thereby increasing the risks of morbidity to mother and baby. Perceived antagonism from hospital staff may also lead to the patient's refusal and resultant delay of recommended medical interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20312/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospital staff should be aware that most home birth providers keep detailed antenatal and intrapartum records and such information may be crucial for patient care after hospital transfer. Good communication between home birth providers and hospital staff will allow conveyance of this information and a smoother transition for the patient.",
"   </p>",
"   <p>",
"    Providers should also be aware that women transferred to the hospital after an attempted home birth may be very disappointed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fearful of hospital transfer; putting such patients at ease may facilitate patient care. The use of the expression \"failed home birth\" is discouraged, as it is unnecessarily negative, as opposed to a neutral expression such as \"home birth transfer.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Planned home birth is uncommon in the United States (0.67 percent of births). After remaining fairly stable over recent years, the rate appears to be rising, suggesting ongoing interest in this approach to childbirth. The Netherlands have the highest rate of planned home birth (30 percent of births). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence of home birth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who opt for home birth are predominantly white non-Hispanic, older, and multiparous. Some common reasons for choosing home birth include a desire for a low-intervention birth with family and friends in a familiar environment, more control of the birth process, and dissatisfaction with hospital care. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Women who choose home birth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large cohort studies using intent-to-treat analysis of midwife-attended, planned, out-of-hospital birth of low risk women in developed countries have reported reduced rates of cesarean birth, perineal lacerations, and medical interventions, and similar rates of maternal and early perinatal morbidity and mortality compared to planned hospital birth. However, there may be a higher rate of late neonatal mortality with planned home birth. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Outcomes of home birth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following are suggested minimum criteria for planning a home birth:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      informed consent",
"     </li>",
"     <li>",
"      singleton cephalic fetus at term",
"     </li>",
"     <li>",
"      absence of preexisting serious medical or obstetrical conditions",
"     </li>",
"     <li>",
"      absence of contraindications to vaginal birth",
"     </li>",
"     <li>",
"      The prenatal care, labor, birth, and postpartum care should be attended by a licensed obstetrical caregiver and there should be a transport plan in case a hospital providing obstetrical care becomes necessary. Ideally, the back-up hospital should provide 24-hour maternity care and should be within 15 minutes of the home. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good communication and mutual respect between home birth providers and hospital staff are essential for patient care and safety when a woman is transferred from home to hospital. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hospital transfer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/1\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 476: Planned home birth. Obstet Gynecol 2011; 117:425.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Nurse-Midwives Position Statement on Home Birth. Washington, DC: ACNM. December, 2005.",
"    </li>",
"    <li>",
"     APHA. Increasing access to out-of-hospital maternity care services through state-regulated and nationally-certified direct-entry midwives. APHA Public Policy Statements, 1948 to present, cumulative Washington, DC 2001.",
"    </li>",
"    <li>",
"     Maternal and Newborn Health/Safe Motherhood Unit of the World Health Organization, Care in Normal Birth: A practical guide. World Health Organization, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/5\">",
"      Hendrix MJ, Evers SM, Basten MC, et al. Cost analysis of the Dutch obstetric system: low-risk nulliparous women preferring home or short-stay hospital birth--a prospective non-randomised controlled study. BMC Health Serv Res 2009; 9:211.",
"     </a>",
"    </li>",
"    <li>",
"     Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2009, National vital statistics reports, National Center for Health Statistics, Hyattsville, MD 2011.",
"    </li>",
"    <li>",
"     MacDorman, M, Menacker, F, Declercq, E. Trends and characteristics of home and other out-of-hospital births in the United States, 1990&ndash;2006. National vital statistics reports 2010; vol 58 no 11. Hyattsville, MD: National Center for Health Statistics.",
"    </li>",
"    <li>",
"     MacDorman M, Declercq E, Mathews TJ. United States Home Births Increase 20 Percent from 2004 to 2008. Birth: Issues in Perinatal Care 2001.",
"    </li>",
"    <li>",
"     QuickStats: Percentage of Births That Were Home Births, by Maternal Race/Ethnicity &mdash; United States, 1990&ndash;2009 www.cdc.gov/mmwr/preview/mmwrhtml/mm6103a6.htm (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     Office for National Statistics. Birth Statistics 2008 Series FM1 No.37 February 2010. file://www.statistics.gov.uk/downloads/theme_population/FM1-37/FM1_37_2008.pdf. (Accessed on May 10, 2010).",
"    </li>",
"    <li>",
"     DeVries R. A Pleasing Birth: Midwives and Maternity Care in the Netherlands, Temple University Press, Philadelphia 2005.",
"    </li>",
"    <li>",
"     National Center for Health Statistics. VitalStats website. Birth data 2010 state and county files. file://www.cdc.gov/nchs/vitalstats.htm (Accessed on December 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/13\">",
"      Vogel L. \"Do it yourself\" births prompt alarm. CMAJ 2011; 183:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/14\">",
"      Declercq E, Macdorman MF, Menacker F, Stotland N. Characteristics of planned and unplanned home births in 19 States. Obstet Gynecol 2010; 116:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/15\">",
"      Wax JR, Pinette MG, Cartin A. Home versus hospital birth--process and outcome. Obstet Gynecol Surv 2010; 65:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/16\">",
"      Boucher D, Bennett C, McFarlin B, Freeze R. Staying home to give birth: why women in the United States choose home birth. J Midwifery Womens Health 2009; 54:119.",
"     </a>",
"    </li>",
"    <li>",
"     Martin, JA, Hamilton, BE, Sutton, PD, et al. Births: final data for 2007. National vital statistics reports, National Center for Health Statistics, Hyattsville, MD 2010.",
"    </li>",
"    <li>",
"     QuickStats: Percentage of Births That Were Home Births, by Maternal Race/Ethnicity &mdash; United States, 1990&ndash;2009* file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6103a6.htm?s_cid=mm6103a6_x (Accessed on January 26, 2012).",
"    </li>",
"    <li>",
"     Rooks J. Midwifery and childbirth in America, Temple University Press, Philadelphia 1997.",
"    </li>",
"    <li>",
"     Kitzinger S, May M. Homebirth: the essential guide to giving birth outside of the hospital., 1st American, Dorling Kindersley, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/21\">",
"      Klee L. Home away from home: the alternative birth center. Soc Sci Med 1986; 23:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/22\">",
"      McClain CS. Perceived risk and choice of childbirth service. Soc Sci Med 1983; 17:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/23\">",
"      Janssen PA, Henderson AD, Vedam S. The experience of planned home birth: views of the first 500 women. Birth 2009; 36:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/24\">",
"      Lindgren HE, R&aring;destad IJ, Christensson K, et al. Perceptions of risk and risk management among 735 women who opted for a home birth. Midwifery 2010; 26:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/25\">",
"      Pang JW, Heffelfinger JD, Huang GJ, et al. Outcomes of planned home births in Washington State: 1989-1996. Obstet Gynecol 2002; 100:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/26\">",
"      Lindgren HE, R&aring;destad IJ, Christensson K, Hildingsson IM. Outcome of planned home births compared to hospital births in Sweden between 1992 and 2004. A population-based register study. Acta Obstet Gynecol Scand 2008; 87:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/27\">",
"      Ackermann-Liebrich U, Voegeli T, G&uuml;nter-Witt K, et al. Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ 1996; 313:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/28\">",
"      Janssen PA, Lee SK, Ryan EM, et al. Outcomes of planned home births versus planned hospital births after regulation of midwifery in British Columbia. CMAJ 2002; 166:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/29\">",
"      de Jonge A, van der Goes BY, Ravelli AC, et al. Perinatal mortality and morbidity in a nationwide cohort of 529,688 low-risk planned home and hospital births. BJOG 2009; 116:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/30\">",
"      Woodcock HC, Read AW, Bower C, et al. A matched cohort study of planned home and hospital births in Western Australia 1981-1987. Midwifery 1994; 10:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/31\">",
"      Johnson KC, Daviss BA. Outcomes of planned home births with certified professional midwives: large prospective study in North America. BMJ 2005; 330:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/32\">",
"      Wiegers TA, Keirse MJ, van der Zee J, Berghs GA. Outcome of planned home and planned hospital births in low risk pregnancies: prospective study in midwifery practices in The Netherlands. BMJ 1996; 313:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/33\">",
"      Janssen PA, Saxell L, Page LA, et al. Outcomes of planned home birth with registered midwife versus planned hospital birth with midwife or physician. CMAJ 2009; 181:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/34\">",
"      Olsen O, Clausen JA. Planned hospital birth versus planned home birth. Cochrane Database Syst Rev 2012; 9:CD000352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/35\">",
"      Mori R, Dougherty M, Whittle M. An estimation of intrapartum-related perinatal mortality rates for booked home births in England and Wales between 1994 and 2003. BJOG 2008; 115:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/36\">",
"      Amelink-Verburg MP, Verloove-Vanhorick SP, Hakkenberg RM, et al. Evaluation of 280,000 cases in Dutch midwifery practices: a descriptive study. BJOG 2008; 115:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/37\">",
"      Kennare RM, Keirse MJ, Tucker GR, Chan AC. Planned home and hospital births in South Australia, 1991-2006: differences in outcomes. Med J Aust 2010; 192:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/38\">",
"      Hutton EK, Reitsma AH, Kaufman K. Outcomes associated with planned home and planned hospital births in low-risk women attended by midwives in Ontario, Canada, 2003-2006: a retrospective cohort study. Birth 2009; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/39\">",
"      Gyte G, Dodwell M, Newburn M, et al. Estimating intrapartum-related perinatal mortality rates for booked home births: when the 'best' available data are not good enough. BJOG 2009; 116:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/40\">",
"      Wax JR, Lucas FL, Lamont M, et al. Maternal and newborn outcomes in planned home birth vs planned hospital births: a metaanalysis. Am J Obstet Gynecol 2010; 203:243.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/41\">",
"      Dowswell T, Thornton JG, Hewison J, et al. Should there be a trial of home versus hospital delivery in the United Kingdom? BMJ 1996; 312:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/42\">",
"      Koehler NU, Solomon DA, Murphy M. Outcomes of a rural Sonoma County home birth practice: 1976-1982. Birth 1984; 11:165.",
"     </a>",
"    </li>",
"    <li>",
"     Michael CA, Janssen PA, Vedam S, Hutton EK, de Jonge A. Planned Home vs Hospital Birth: A Meta-Analysis Gone Wrong. Medscape Ob/Gyn &amp; Women's Health (online). file://www.medscape.com/viewarticle/739987. (Accessed on June 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/44\">",
"      Birthplace in England Collaborative Group, Brocklehurst P, Hardy P, et al. Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England national prospective cohort study. BMJ 2011; 343:d7400.",
"     </a>",
"    </li>",
"    <li>",
"     https://www.npeu.ox.ac.uk/birthplace. (Accessed on December 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/46\">",
"      Schroeder E, Petrou S, Patel N, et al. Cost effectiveness of alternative planned places of birth in woman at low risk of complications: evidence from the Birthplace in England national prospective cohort study. BMJ 2012; 344:e2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/47\">",
"      van der Kooy J, Poeran J, de Graaf JP, et al. Planned home compared with planned hospital births in the Netherlands: intrapartum and early neonatal death in low-risk pregnancies. Obstet Gynecol 2011; 118:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/48\">",
"      Ecker J, Minkoff H. Home birth: what are physicians' ethical obligations when patient choices may carry increased risk? Obstet Gynecol 2011; 117:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/49\">",
"      Chervenak FA, McCullough LB, Brent RL, et al. Planned home birth: the professional responsibility response. Am J Obstet Gynecol 2013; 208:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/50\">",
"      Janssen PA, Lee SK, Ryan ER, Saxell L. An evaluation of process and protocols for planned home birth attended by regulated midwives in British Columbia. J Midwifery Womens Health 2003; 48:138.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.livestrong.com/article/534876-holistic-approach-to-strep-b-in-pregnancy/. (Accessed on November 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/52\">",
"      Bishara RM. GBS in a homebirth setting. Midwifery Today Int Midwife 2006; :32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/53\">",
"      Davis-Floyd R. Home-birth emergencies in the US and Mexico: the trouble with transport. Soc Sci Med 2003; 56:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20312/abstract/54\">",
"      Declercq ER. The trials of Hanna Porn: the campaign to abolish midwifery in Massachusetts. Am J Public Health 1994; 84:1022.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4454 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20312=[""].join("\n");
var outline_f19_53_20312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNITED STATES NATALITY DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence of home birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Birth attendant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WOMEN WHO CHOOSE HOME BIRTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Demographics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reasons for choosing home birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OUTCOMES OF HOME BIRTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Limitations of available data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Evidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H553115807\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Prospective studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14539050\">",
"      - Retrospective studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26869395\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Provider",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2720169\">",
"      Group B streptococcus and home birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Organization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Newborn care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hospital transfer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/27/34236\" title=\"table 1\">",
"      Birth attendant home birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/18/16684\" title=\"table 2\">",
"      Moms who deliver at home",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25048?source=related_link\">",
"      Birth centers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/1/5141?source=related_link\">",
"      Precipitous birth not occurring on a labor and delivery unit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_53_20313="Complications, diagnosis, and treatment of odontogenic infections";
var content_f19_53_20313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications, diagnosis, and treatment of odontogenic infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/53/20313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/53/20313/contributors\">",
"     Anthony W Chow, MD, FRCPC, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/53/20313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/53/20313/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/53/20313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/53/20313/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/53/20313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic infections, consisting primarily of dental caries and periodontal disease (gingivitis and periodontitis), are common and have local (eg, tooth loss) and, in some cases, systemic implications. In the United States, it is estimated that 25 percent of adults over the age of 60 have lost all their teeth (edentulism), approximately one-half from periodontal disease and one-half from dental caries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to producing pain and discomfort, odontogenic infections can extend beyond natural barriers and result in potentially life-threatening complications, such as infections of the deep fascial spaces of the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periodontal infection can also be associated with a number of systemic disorders. These include fever of unknown origin, bacteremic seeding of heart valves and prosthetic devices, preterm birth of low birth weight children, and an increased risk for coronary heart disease and cerebrovascular events.",
"   </p>",
"   <p>",
"    The complications, diagnosis, and treatment of odontogenic infections will be reviewed here. The epidemiology, pathogenesis, and clinical manifestations of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=see_link\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppurative odontogenic infections may extend to potential fascial spaces in the orofacial area (orofacial space infections), or deep in the head and neck (peripharyngeal space infections). The latter complication is often life-threatening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, odontogenic infections may spread contiguously to cause osteomyelitis of the jaw, or hematogenously to produce systemic illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Orofacial space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial orofacial space infections can involve the buccal, submental, masticator, canine, and infratemporal spaces. The location of the space infection can assist in recognizing the underlying infected tooth (",
"    <a class=\"graphic graphic_table graphicRef71760 \" href=\"UTD.htm?25/14/25837\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If unrecognized and untreated, these infections are potentially serious since they can spread contiguously into the deeper fascial spaces of the head and neck, such as the submandibular, lateral pharyngeal, and retropharyngeal spaces, or into the carotid sheath. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spread of infection into the deeper fascial spaces of the head and neck is suggested by the finding of trismus (the inability to open the jaw). Trismus indicates pressure or infection of the muscles of mastication (the masseter and the pterygoids) or involvement of the motor branch of the trigeminal nerve. Such infections can spread intracranially to cause purulent meningitis or subdural empyema, and caudally to result in aspiration, airway obstruction, or fatal necrotizing mediastinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Buccal and submental spaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections arising from mandibular or maxillary bicuspid and molar teeth tend to extend in a lateral or buccal direction. The relation of the root apices to the origins of the buccinator muscle determines whether infection will exit intraorally into the buccal vestibule or extraorally into the buccal space (",
"    <a class=\"graphic graphic_figure graphicRef77988 \" href=\"UTD.htm?6/14/6368\">",
"     figure 1",
"    </a>",
"    ). Infection of the buccal space is readily diagnosed because of marked cheek swelling with minimal trismus and systemic symptoms.",
"   </p>",
"   <p>",
"    Involvement of a mandibular incisor can perforate below the mentalis muscle and present as a submental space infection. The chin appears grossly swollen and is firm and erythematous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Masticator spaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masticator spaces consist of the masseteric, pterygoid, and temporal spaces, all of which are well differentiated but intercommunicate with each other as well as with the buccal, submandibular, and lateral pharyngeal spaces (",
"    <a class=\"graphic graphic_figure graphicRef80359 \" href=\"UTD.htm?0/23/372\">",
"     figure 2",
"    </a>",
"    ). Infection of the masticator spaces arises most frequently from molar teeth, particularly the third molars (wisdom teeth). The clinical hallmark of masticator space infection is trismus and pain in the area of the body or ramus of the mandible.",
"   </p>",
"   <p>",
"    Swelling may not be a prominent finding, especially in the masseteric compartment, since the infection is beneath large muscle masses that can obscure or prevent clinically apparent swelling. When present, swelling tends to be brawny and indurated, suggesting the possibility of cervicofacial actinomycosis or mandibular osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21559?source=see_link\">",
"     \"Cervicofacial actinomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection of the deep temporal space usually originates from involvement of the posterior maxillary molar teeth. Little external swelling is observed early in the course; if present, it usually affects the preauricular region and an area over the zygomatic arch. As infection progresses, the cheek, eyelids, and whole side of the face may be involved. Infection may extend directly into the orbit via the inferior orbital fissure and produce proptosis, optic neuritis, and abducens nerve palsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Canine and infratemporal spaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the maxillary incisors and canines may result in a canine space infection, which manifests as dramatic swelling of the upper lip, canine fossa, and frequently the periorbital tissues. Pain is usually moderate, and systemic signs are minimal. Occasionally, direct extension of infection into the adjoining antrum leads to purulent maxillary sinusitis.",
"   </p>",
"   <p>",
"    The infratemporal space is bounded medially by the lateral plate of the pterygoid process and the pharynx, posteriorly by the parotid gland, anteriorly by the maxilla, and superiorly by the roof of the infratemporal fossa, adjacent to which is the inferior orbital fissure (",
"    <a class=\"graphic graphic_figure graphicRef80359 \" href=\"UTD.htm?0/23/372\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Primary infections of the infratemporal fossa usually originate from involvement of the posterior maxillary molar teeth, particularly the third molar. Injection of local anesthetic into this area for a dental restoration may predispose to infection.",
"   </p>",
"   <p>",
"    Clinically, marked trismus and pain are present, but very little swelling is observed early in the course. Late manifestations are similar to those of temporal space infections, including extension into the orbit through the inferior orbital fissure. In addition, if the infection extends internally, it can involve an area close to the lateral pharyngeal wall, resulting in dysphagia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Osteomyelitis of the jaw",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic infections can spread contiguously to cause osteomyelitis of the jaw. The mandible is much more susceptible to osteomyelitis than the maxilla, primarily because the cortical plates of the former are thin and vascular supply to the medullary tissues is relatively poor. Despite this, osteomyelitis secondary to odontogenic infection is relatively uncommon. When it does occur, there is usually a predisposing condition, such as compound fracture, irradiation, diabetes mellitus, or steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With initiation of infection, the intramedullary pressure markedly increases, further compromising blood supply and leading to bone necrosis. Pus travels through the Haversian and perforating canals, accumulates beneath the periosteum, and elevates it from the cortex. If pus continues to accumulate, the periosteum is eventually penetrated, and mucosal or cutaneous abscesses and fistulae can develop. Areas at greatest risk of perforation in the mandible are the lingual aspect in the region of molar teeth, and anteriorly on the buccal aspect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the inflammatory process becomes more chronic, granulation tissue is formed. Spicules of necrotic and nonviable bone may become either totally isolated (sequestrum) or encased in a sheath of new bone (involucrum).",
"   </p>",
"   <p>",
"    Severe mandibular pain is a common symptom of jaw osteomyelitis and can be accompanied by anesthesia or hypoesthesia on the affected side. In protracted cases, mandibular trismus may develop.",
"   </p>",
"   <p>",
"    A clinical variant of osteomyelitis of the jaw is Garre's chronic sclerosing osteomyelitis or proliferative periostitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/5\">",
"     5",
"    </a>",
"    ]. This entity usually occurs in children and young adults following a periapical infection of the mandibular first molar. It is a nonsuppurative form of osteomyelitis characterized by a localized, hard, nontender swelling over the mandible. On radiographic imaging, the newly formed periosteal bone appears as layers outside the cortex, giving a characteristic \"onion skin\" appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/6\">",
"     6",
"    </a>",
"    ]. Actinomycosis and radiation necrosis are two common causes of this form of osteomyelitis of the jaw [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related clinical entity, characterized by exposed necrotic bone in the maxillofacial region, is osteonecrosis of the jaw associated with long-term administration of bisphosphonates for the treatment of osteoporosis or cancer. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link&amp;anchor=H435805#H435805\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Other causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hematogenous dissemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to contiguous spread, odontogenic infections can disseminate hematogenously to seed native or prosthetic heart valves, joints, or other devices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/8\">",
"     8",
"    </a>",
"    ]. Although bacteremia can occur following almost all types of dental manipulations, including flossing, scaling, even tooth brushing and chewing hard candy, such episodes are usually transient and inconsequential in healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, the bacteremia in patients with dental caries and periodontal disease tends to be more frequent and sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/10\">",
"     10",
"    </a>",
"    ], and is a potentially important cause of infective endocarditis in elderly patients, who may be more susceptible due to age-related degenerative or calcified valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dental sources of bacteremia in elderly adults are of increasing concern for those undergoing prosthetic heart valve implantation or prosthetic joint replacement. It has been recommended that routine dental assessment be performed in all patients undergoing valve surgery, and that appropriate therapeutic interventions be initiated whenever possible before valve implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/12\">",
"     12",
"    </a>",
"    ]. Recommendations regarding the use of antimicrobial prophylaxis for the prevention of bacterial endocarditis in selected patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of prosthetic joint infection as a consequence of bacteremia following dental procedures has been controversial. This is also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of prosthetic joint infections\", section on 'Dental procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Association with cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between poor oral health and chronic periodontitis with coronary and cerebrovascular disease has been well established epidemiologically [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/13\">",
"     13",
"    </a>",
"    ]. The relevant data and possible mechanisms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\", section on 'Association with cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining appropriate material for culture and processing it properly are important in the diagnosis of odontogenic infections. In addition, imaging techniques to assess the extent of involvement are essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Specimen collection and processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the difficulties in defining etiologic agents for odontogenic infections is the presence of normal resident oral flora. For closed space infections, it is imperative that the normal oral flora be excluded during specimen collection in order to interpret culture results. Needle aspiration of loculated pus by an extraoral approach is desirable, and specimens should be transported immediately to the laboratory under anaerobic conditions.",
"   </p>",
"   <p>",
"    However, contamination by the resident oral flora is inevitable for intraoral lesions. In this setting, direct microscopic examination of stained smears often provides more useful information than culture results from surface swabs. Gram stain and acid fast stains for bacteria and potassium hydroxide preparations for fungi should be routinely performed on these specimens. Tissue biopsies should be routinely examined for histopathologic evidence of acute or chronic inflammation and infection. Specific microbial agents, including certain bacterial, mycobacterial, fungal and viral infections, can sometimes be detected by immunofluorescence or polymerase chain reaction.",
"   </p>",
"   <p>",
"    Patients with chronic osteomyelitis often have soft tissue swelling and draining fistulas. Aspirates from the adjacent soft tissue swelling may be valuable. In contrast, cultures from sinus tracts can be misleading, since there is communication with the external environment. Thus, microorganisms that are isolated could represent colonization of the sinus tract rather than the organism responsible for the infected bone. Bone biopsies for histopathology and culture are often required for definitive diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of imaging technique varies with the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A panoramic or periapical radiograph may reveal the extent of advanced periodontitis or the presence of periapical abscess.",
"     </li>",
"     <li>",
"      Computed tomography (CT) is particularly sensitive for osseous structures and remains the imaging modality of choice for assessment of most odontogenic infections [",
"      <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/14\">",
"       14",
"      </a>",
"      ]. Dental amalgam used in fillings may cause metallic streaking artifact on CT and obscure the region of interest. This problem can be minimized with multidetector CT imaging.",
"     </li>",
"     <li>",
"      CT and particularly magnetic resonance (MR) have become the preferred imaging modalities for the localization of deep fascial space infections of the head and neck. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link&amp;anchor=H988692187#H988692187\">",
"       \"Deep neck space infections\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A lateral radiograph of the neck may demonstrate compression or deviation of the tracheal air column, or the presence of gas within necrotic soft tissues. In retropharyngeal infections, lateral radiography of the cervical spine or CT scanning can help determine if the infection is in the retropharyngeal space or the prevertebral space. The former suggests an odontogenic source, while the latter suggests involvement of the cervical spine.",
"     </li>",
"     <li>",
"      Technetium bone scanning, used in combination with gallium or indium-labeled white blood cell scanning, is particularly useful for the diagnosis of acute or chronic osteomyelitis, and for the differentiation of infection or trauma from malignancy. In acute osteomyelitis, both the bone scan and gallium scan are likely to be positive. In chronic osteomyelitis, the technetium scans may or may not be positive, while gallium or indium-labeled scans are often negative. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"       \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, bone neoplasms can be associated with a positive technetium scan but negative gallium or indium scan. Although the scintigraphic findings may be suggestive, only bone biopsy will definitively differentiate infection from malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THERAPEUTIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meticulous attention to oral hygiene is the most important strategy for effective control of supragingival and subgingival plaque that, in turn, is essential for both caries prevention and the treatment of periodontitis. Individuals with physical or mental limitations who cannot adequately perform oral hygiene by themselves should receive daily oral hygiene by care providers. More frequent visits to dentists and use of electric toothbrushes should also be considered in these patients. Regular check-ups and prompt restorative care by dental professionals should be actively promoted.",
"   </p>",
"   <p>",
"    With the recognition of the microbial specificity of odontogenic infections, topical antiseptics and systemic antibiotics have played an increasingly important role in the control and treatment of both dental caries and periodontal disease (",
"    <a class=\"graphic graphic_table graphicRef77718 \" href=\"UTD.htm?1/14/1261\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\", section on 'Microbial specificity in odontogenic infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for dental extractions has been reduced considerably by the availability of improved dental restorative materials, such as bonding and fluoride-releasing agents, as well as improved restorative care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dental caries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caries management with restorative therapy (eg, fillings) is the preferred therapeutic approach in many countries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/15\">",
"     15",
"    </a>",
"    ]. However, restorative therapy must be combined with preventive measures, since restorations have relatively short durability and new caries may form at the margins of restorations if the causes of the disease persist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. Caries prevention is discussed below. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulpitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulpitis, inflammation of the dental pulp, occurs when progression of dental caries exposes the dental pulp, leading to infection (",
"    <a class=\"graphic graphic_figure graphicRef65240 \" href=\"UTD.htm?35/4/35907\">",
"     figure 3",
"    </a>",
"    ). The early and dominant symptom of acute pulpitis is a severe toothache that can be elicited by thermal changes, especially cold drinks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\", section on 'Pulpitis and periapical abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulpitis can be classified as reversible or irreversible. Reversible pulpitis occurs when caries encroach on the pulp and is associated with mild inflammation of the pulp. Irreversible pulpitis refers to ongoing inflammation within the pulp chamber with rapid buildup of pressure, occlusion of blood vessels at the apical foramen, ischemia, and necrosis of the pulp tissue.",
"   </p>",
"   <p>",
"    Irreversible pulpitis is characterized by acute and intense pain, and is one of the most frequent reasons that patients seek emergency dental care. Apart from removal of the tooth, the customary approach to relieving the pain of irreversible pulpitis is by drilling into the tooth, removing the inflamed pulp (nerve), and cleaning the root canal. A minority of dentists begins with a trial of antibiotics and analgesics, although there is no proof of benefit from this approach.",
"   </p>",
"   <p>",
"    A 2006 literature review found only one randomized controlled trial that compared treatment with systemic antibiotics to placebo in irreversible pulpitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/16\">",
"     16",
"    </a>",
"    ]. In this study, 40 patients were treated with analgesics and randomly assigned to either penicillin or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/17\">",
"     17",
"    </a>",
"    ]. No operative endodontic treatment was performed. Although the study was limited by small sample size, no significant difference in pain intensity or use of analgesics was noted between the two groups. More recently, photo-activated disinfection has been evaluated as an aid to mechanical irrigation in eradicating bacterial counts within the root canal during endodontic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/18\">",
"     18",
"    </a>",
"    ]. It was highly effective in eliminating endodontic pathogens from the root canal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. It remains to be determined whether this approach provides incremental benefit compared to conventional endodontic treatment in symptom relief or disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute gingivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute simple gingivitis rarely requires systemic antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine",
"    </a>",
"    0.12 percent oral rinse can be used in most cases. Exceptions include patients with rapidly advancing disease, severe pain, or HIV infection in whom systemic therapy is indicated. Possible regimens include penicillin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef77718 \" href=\"UTD.htm?1/14/1261\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Acute necrotizing ulcerative gingivitis, also known as Vincent's angina or trench mouth, should be treated with systemic antimicrobials, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef77718 \" href=\"UTD.htm?1/14/1261\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/21,23\">",
"     21,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Periodontitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to microbial specificity in various forms of periodontitis, certain types of severe periodontitis are amenable to systemic antimicrobials in conjunction with mechanical debridement (scaling and root planing) (",
"    <a class=\"graphic graphic_table graphicRef77718 \" href=\"UTD.htm?1/14/1261\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/24\">",
"     24",
"    </a>",
"    ]. This approach has often obviated the need for radical surgical resection of periodontal tissues.",
"   </p>",
"   <p>",
"    The efficacy of antimicrobial therapy was evaluated in a double-blind trial in which 94 patients with advanced periodontitis were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg PO twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg daily) or placebo for one or two weeks in conjunction with rigorous mechanical debridement of the root surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/25\">",
"     25",
"    </a>",
"    ]. Antimicrobial therapy reduced the need for radical surgery by 81 percent compared to placebo.",
"   </p>",
"   <p>",
"    The efficacy of local antibiotic therapy in conjunction with scaling and root planning in chronic periodontitis has also been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. Adjunctive local antibiotics have been shown to significantly reduce pocket depth or degree of periodontal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/26\">",
"     26",
"    </a>",
"    ]. Effective agents include 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    spheres (Arestub), 10 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    hyclate extended release liquid (Atridox), and 25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    gel (Elyzol) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/22,26,27\">",
"     22,26,27",
"    </a>",
"    ]. These agents release controlled amounts of the antibiotic beneath the gum and are used in conjunction with scaling and root planing to reduce pocket depth in adult periodontitis.",
"   </p>",
"   <p>",
"    In localized juvenile periodontitis, systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    therapy directed against Actinobacillus actinomycetemcomitans (a HACEK infection) and combined with local periodontal treatment has yielded excellent results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/22\">",
"     22",
"    </a>",
"    ]. Unfortunately, the administration of tetracycline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    to children eight years of age or younger can cause staining of the permanent dentition and is not generally recommended. Furthermore, tetracycline resistance among periodontal pathogens has been increasingly recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The routine use of systemic antimicrobials to prevent postoperative infections following oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    periodontal surgery in a healthy host remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/29\">",
"     29",
"    </a>",
"    ]. In the setting of third molar extractions, a single dose of intravenous penicillin was shown to significantly reduce the incidence of surgical site infection in a double-blind placebo-controlled trial (8.5 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Suppurative odontogenic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important therapeutic modality for pyogenic odontogenic infections is surgical drainage and removal of necrotic tissue. Needle aspiration by the extraoral route can be particularly helpful both for microbiologic sampling and for evacuation of pus. The need for definitive restoration or extraction of the infected tooth, the primary source of infection, is usually readily apparent. Deep periodontal scaling and endodontic treatments with root filling is required in most instances.",
"   </p>",
"   <p>",
"    Effective surgical management requires a thorough understanding of the most likely anatomic routes of spread. The neighboring potential fascial spaces should be carefully and systematically surveyed. The optimum timing for incision and drainage is equally important. Premature incision into an area of cellulitis in an ill-conceived search for pus can disrupt the normal physiologic barrier and cause extension of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy can halt the local spread of infection and prevent hematogenous dissemination. Antimicrobial agents are generally indicated if fever and regional lymphadenopathy are present, or when infection has perforated the bony cortex and spread into surrounding soft tissue. Severely immunocompromised patients are particularly at risk for spreading orofacial infections, and empiric broad spectrum antimicrobial therapy in these patients is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of specific antibiotics for the treatment of odontogenic infections is based more upon knowledge of the indigenous organisms that colonize the teeth, gums, and mucous membranes, as well as specific cariogenic and periodontopathic pathogens associated with clinical disease, rather than upon the results of culture and susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beta-lactamase production among oral anaerobes, particularly pigmented Prevotella spp and Fusobacterium spp, is increasingly recognized, and treatment failure with penicillin alone has been well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, penicillin monotherapy is no longer recommended.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     Ampicillin-sulbactam",
"    </a>",
"    (3 g IV every six hours) provides extended coverage against oral anaerobes, including those that produce beta-lactamases, and is the treatment of choice (",
"    <a class=\"graphic graphic_table graphicRef70669 \" href=\"UTD.htm?38/38/39532\">",
"     table 3",
"    </a>",
"    ). An alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2 to 4 million units IV every four to six hours) in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg IV or orally every eight hours).",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is highly active against anaerobic gram-negative bacilli and spirochetes, it is only moderately active against anaerobic cocci and is not active against aerobes, including streptococci. As a result, it should not be used as a single agent in odontogenic infections except in acute necrotizing gingivitis and advanced periodontitis.",
"   </p>",
"   <p>",
"    Penicillin-allergic patients should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 mg IV every eight hours).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    are not recommended because of increasing resistance among some strains of streptococci and their lack of optimal anaerobic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the compromised host, such as the patient with leukemia and severe neutropenia after chemotherapy, it is prudent to cover for facultative gram-negative bacilli (including Pseudomonas spp) as well, and agents with broad-spectrum activity against both aerobes and anaerobes are desirable. Appropriate regimens are described in the table (",
"    <a class=\"graphic graphic_table graphicRef70669 \" href=\"UTD.htm?38/38/39532\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of osteomyelitis of the jaw is complicated by the presence of teeth and persistent exposure to the oral environment. Antibiotic therapy needs to be prolonged, often for weeks to months.",
"   </p>",
"   <p>",
"    Adjuvant therapy with hyperbaric oxygen, if available, may hasten the healing process, particularly when combined with surgery, but data supporting this are inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical management, including sequestrectomy, saucerization, decortication, and closed-wound suction irrigation, is occasionally necessary. Rarely, in advanced cases, the entire segment of the infected jaw has to be resected [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most cost-effective measure for reducing dental caries is fluoridation of public water supplies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/37\">",
"     37",
"    </a>",
"    ]. Fluoride forms a complex with the apatite crystals in dentin by replacing the hydroxyl group, thereby lending strength to the entire structure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/37\">",
"     37",
"    </a>",
"    ]. Fluoride also promotes remineralization of carious lesions and exerts a bacteriostatic effect.",
"   </p>",
"   <p>",
"    In addition to fluoridated water, brushing two to three times daily with a fluoridated toothpaste (1000 ppm of fluoride, usually as sodium fluoride 1.1 percent or stannous fluoride 0.4 percent) effectively delivers fluoride to the tooth-plaque surface [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/38\">",
"     38",
"    </a>",
"    ]. In high-risk individuals, additional fluoride therapy in the form of fluoride varnishes (22,600 ppm fluoride as five percent sodium fluoride, professionally applied three or four times a year) has been effective in caries prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key for the prevention and control of dental caries and advanced periodontitis is the active promotion of oral hygiene. The components of such a regimen include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regular brushing with a fluoridated toothpaste and dental flossing after each meal.",
"     </li>",
"     <li>",
"      Dietary counseling to reduce the ingestion of sugar-rich foods or beverages.",
"     </li>",
"     <li>",
"      Use of topical fluorides and oral antimicrobial rinses, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      for high-risk patients.",
"     </li>",
"     <li>",
"      Modification of risk factors, such as smoking cessation.",
"     </li>",
"     <li>",
"      Overcoming the reluctance for regular visits to dental professionals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to dispel the common misconception by physicians and patients that progressive dental caries, gingival disease, and loss of teeth is an inevitable and irreversible part of aging. The current lack of motivation of both patients and healthcare providers for regular and rigorous preventative dental care must be reversed.",
"   </p>",
"   <p>",
"    A variety of other measures have been effective for caries prevention. None of these measures is routinely applied in clinical practice, but they are useful in selected patients with rampant caries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Xylitol gum, a nonfermentable five-carbon sugar, as a sugar substitute between meals.",
"     </li>",
"     <li>",
"      Oral antimicrobial rinses with 0.12 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      help to control dental plaque bacteria, but have no proven effect on dental caries [",
"      <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. In addition, chlorhexidine has a bitter taste, stains the enamel and tongue, and prolonged application can promote the emergence of resistant microorganisms.",
"     </li>",
"     <li>",
"      Among topical antibiotics, only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      has been shown to reduce dental caries with some degree of success in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/39,41\">",
"       39,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccines based upon various immunogens derived from Streptococcus mutans, the principal bacterial agent associated with dental caries, have been explored [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the prospect for an effective and safe vaccine remains remote and unlikely to be available for clinical application in the near future. The need for and appropriate frequency of routine dental scaling and polishing in patients at low risk for periodontal disease is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/53/20313/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H370943006\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations regarding the use of antimicrobial prophylaxis to prevent bacterial endocarditis and prosthetic joint infections in selected patients undergoing dental procedures are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of prosthetic joint infections\", section on 'Dental procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172605008\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Odontogenic infections, consisting primarily of dental caries and periodontal disease (gingivitis and periodontitis), are common and have local (eg, tooth loss) and, in some cases, systemic implications. Suppurative odontogenic infections may extend to potential fascial spaces in the orofacial area (orofacial space infections), or deep in the head and neck (peripharyngeal space infections). The latter complication is often life threatening. Odontogenic infections can also result in osteomyelitis of the jaw or hematogenous dissemination, which may in turn cause endocarditis or prosthetic joint infections. &nbsp;(See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For closed space infections, it is imperative that the normal oral flora be excluded during specimen collection in order to interpret culture results. Needle aspiration of loculated pus by an extraoral approach is desirable, and specimens should be transported immediately to the laboratory under anaerobic conditions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Specimen collection and processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of imaging technique varies with the clinical setting. Computed tomography (CT) is particularly sensitive for osseous structures and remains the imaging modality of choice for assessment of most odontogenic infections. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Imaging techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meticulous attention to oral hygiene is the most important strategy for effective control of supragingival and subgingival plaque that, in turn, is essential for both caries prevention and the treatment of periodontitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Therapeutic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulpitis, inflammation of the dental pulp, occurs when progression of dental caries exposes the dental pulp, leading to infection (",
"      <a class=\"graphic graphic_figure graphicRef65240 \" href=\"UTD.htm?35/4/35907\">",
"       figure 3",
"      </a>",
"      ). The early and dominant symptom of acute pulpitis is a severe toothache that can be elicited by thermal changes, especially cold drinks. Apart from removal of the tooth, the customary approach to relieving the pain of irreversible pulpitis is by drilling into the tooth, removing the inflamed pulp (nerve), and cleaning the root canal. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pulpitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute simple gingivitis rarely requires systemic antimicrobial therapy.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       Chlorhexidine",
"      </a>",
"      0.12 percent oral rinse can be used in most cases. Exceptions include patients with rapidly advancing disease, severe pain, or HIV infection in whom systemic therapy is indicated. Possible regimens include penicillin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef77718 \" href=\"UTD.htm?1/14/1261\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute gingivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute necrotizing ulcerative gingivitis, also known as Vincent's angina or trench mouth, should be treated with systemic antimicrobials, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef77718 \" href=\"UTD.htm?1/14/1261\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute gingivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain types of severe periodontitis are amenable to systemic antimicrobials in conjunction with mechanical debridement (scaling and root planing) (",
"      <a class=\"graphic graphic_table graphicRef77718 \" href=\"UTD.htm?1/14/1261\">",
"       table 2",
"      </a>",
"      ). This approach has often obviated the need for radical surgical resection of periodontal tissues. For chronic periodontitis, a topical antibiotic approach is used in conjunction with scaling and root planing.(See",
"      <a class=\"local\" href=\"#H18\">",
"       'Periodontitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important therapeutic modality for pyogenic odontogenic infections is surgical drainage and removal of necrotic tissue. Needle aspiration by the extraoral route can be particularly helpful both for microbiologic sampling and for evacuation of pus. The need for definitive restoration or extraction of the infected tooth, the primary source of infection, is usually readily apparent. Deep periodontal scaling and endodontic treatments with root filling is required in most instances. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Suppurative odontogenic infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pyogenic odontogenic infections, in addition to surgical management, antimicrobial agents are generally indicated if fever and regional lymphadenopathy are present, or when infection has perforated the bony cortex and spread into surrounding soft tissue.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (3 g IV every six hours) provides extended coverage against oral anaerobes, including those that produce beta-lactamases, and is the treatment of choice in immunocompetent patients (",
"      <a class=\"graphic graphic_table graphicRef70669 \" href=\"UTD.htm?38/38/39532\">",
"       table 3",
"      </a>",
"      ). An alternative is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (2 to 4 million units IV every four to six hours) in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV or orally every eight hours). Penicillin-allergic patients should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 mg IV every eight hours). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The single most cost-effective measure for reducing dental caries is fluoridation of public water supplies. Other preventive measures include regular brushing with a fluoridated toothpaste, dental flossing, and reducing the ingestion of sugar-rich foods or beverages. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations regarding the use of antimicrobial prophylaxis to prevent bacterial endocarditis and prosthetic joint infections in selected patients undergoing dental procedures are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention of prosthetic joint infections\", section on 'Dental procedures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/1\">",
"      Beltr&aacute;n-Aguilar ED, Barker LK, Canto MT, et al. Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis--United States, 1988-1994 and 1999-2002. MMWR Surveill Summ 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/2\">",
"      Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999; 70:13.",
"     </a>",
"    </li>",
"    <li>",
"     Chow AW. Infections of the oral cavity, neck and head. In: Principles and Practice of Infectious Diseases, 7, Mandell GL, Bennet JE, Dolin R.  (Eds), Elsevier Churchill Livingstone, Philadelphia 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/4\">",
"      Prasad KC, Prasad SC, Mouli N, Agarwal S. Osteomyelitis in the head and neck. Acta Otolaryngol 2007; 127:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/5\">",
"      Tong AC, Ng IO, Yeung KM. Osteomyelitis with proliferative periostitis: an unusual case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/6\">",
"      Kannan SK, Sandhya G, Selvarani R. Periostitis ossificans (Garr&egrave;'s osteomyelitis) radiographic study of two cases. Int J Paediatr Dent 2006; 16:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/7\">",
"      Sharkawy AA. Cervicofacial actinomycosis and mandibular osteomyelitis. Infect Dis Clin North Am 2007; 21:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/8\">",
"      Bartzokas CA, Johnson R, Jane M, et al. Relation between mouth and haematogenous infection in total joint replacements. BMJ 1994; 309:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/9\">",
"      Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis 2010; 50:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/10\">",
"      Takai S, Kuriyama T, Yanagisawa M, et al. Incidence and bacteriology of bacteremia associated with various oral and maxillofacial surgical procedures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/11\">",
"      Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 2008; 168:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/12\">",
"      Terezhalmy GT, Safadi TJ, Longworth DL, Muehrcke DD. Oral disease burden in patients undergoing prosthetic heart valve implantation. Ann Thorac Surg 1997; 63:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/13\">",
"      Suzuki J, Aoyama N, Ogawa M, et al. Periodontitis and cardiovascular diseases. Expert Opin Ther Targets 2010; 14:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/14\">",
"      Hurley MC, Heran MK. Imaging studies for head and neck infections. Infect Dis Clin North Am 2007; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/15\">",
"      Selwitz RH, Ismail AI, Pitts NB. Dental caries. Lancet 2007; 369:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/16\">",
"      Keenan JV, Farman AG, Fedorowicz Z, Newton JT. A Cochrane systematic review finds no evidence to support the use of antibiotics for pain relief in irreversible pulpitis. J Endod 2006; 32:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/17\">",
"      Nagle D, Reader A, Beck M, Weaver J. Effect of systemic penicillin on pain in untreated irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/18\">",
"      Schlafer S, Vaeth M, H&oslash;rsted-Bindslev P, Frandsen EV. Endodontic photoactivated disinfection using a conventional light source: an in vitro and ex vivo study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/19\">",
"      Williams JA, Pearson GJ, Colles MJ. Antibacterial action of photoactivated disinfection {PAD} used on endodontic bacteria in planktonic suspension and in artificial and human root canals. J Dent 2006; 34:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/20\">",
"      Bonsor SJ, Nichol R, Reid TM, Pearson GJ. Microbiological evaluation of photo-activated disinfection in endodontics (an in vivo study). Br Dent J 2006; 200:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/21\">",
"      Hull MW, Chow AW. An Approach to Oral Infections and Their Management. Curr Infect Dis Rep 2005; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/22\">",
"      Krayer JW, Leite RS, Kirkwood KL. Non-surgical chemotherapeutic treatment strategies for the management of periodontal diseases. Dent Clin North Am 2010; 54:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/23\">",
"      Baker KA, Fotos PG. The management of odontogenic infections. A rationale for appropriate chemotherapy. Dent Clin North Am 1994; 38:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/24\">",
"      Slots J, Ting M. Systemic antibiotics in the treatment of periodontal disease. Periodontol 2000 2002; 28:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/25\">",
"      Loesche WJ, Giordano J, Soehren S, et al. Nonsurgical treatment of patients with periodontal disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/26\">",
"      Bonito AJ, Lux L, Lohr KN. Impact of local adjuncts to scaling and root planing in periodontal disease therapy: a systematic review. J Periodontol 2005; 76:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/27\">",
"      Salvi GE, Mombelli A, Mayfield L, et al. Local antimicrobial therapy after initial periodontal treatment. J Clin Periodontol 2002; 29:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/28\">",
"      Warburton PJ, Palmer RM, Munson MA, Wade WG. Demonstration of in vivo transfer of doxycycline resistance mediated by a novel transposon. J Antimicrob Chemother 2007; 60:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/29\">",
"      Little JW, Falace DA, Miller CS, Rhodus NL. Antibiotic prophylaxis in dentistry: an update. Gen Dent 2008; 56:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/30\">",
"      Halpern LR, Dodson TB. Does prophylactic administration of systemic antibiotics prevent postoperative inflammatory complications after third molar surgery? J Oral Maxillofac Surg 2007; 65:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/31\">",
"      Lopes DR, Peres MP, Levin AS. Randomized study of surgical prophylaxis in immunocompromised hosts. J Dent Res 2011; 90:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/32\">",
"      Brook I. Antibiotic resistance of oral anaerobic bacteria and their effect on the management of upper respiratory tract and head and neck infections. Semin Respir Infect 2002; 17:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/33\">",
"      Poeschl PW, Spusta L, Russmueller G, et al. Antibiotic susceptibility and resistance of the odontogenic microbiological spectrum and its clinical impact on severe deep space head and neck infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/34\">",
"      Rossi-Fedele G, Scott W, Spratt D, et al. Incidence and behaviour of Tn916-like elements within tetracycline-resistant bacteria isolated from root canals. Oral Microbiol Immunol 2006; 21:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/35\">",
"      Chrcanovic BR, Reher P, Sousa AA, Harris M. Osteoradionecrosis of the jaws--a current overview--Part 2: dental management and therapeutic options for treatment. Oral Maxillofac Surg 2010; 14:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/36\">",
"      Lentrodt S, Lentrodt J, K&uuml;bler N, M&ouml;dder U. Hyperbaric oxygen for adjuvant therapy for chronically recurrent mandibular osteomyelitis in childhood and adolescence. J Oral Maxillofac Surg 2007; 65:186.",
"     </a>",
"    </li>",
"    <li>",
"     Murray, JJ. Appropriate use of fluorides for human health. Geneva: World Health Organization, 1986. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/38\">",
"      Hicks J, Garcia-Godoy F, Flaitz C. Biological factors in dental caries: role of remineralization and fluoride in the dynamic process of demineralization and remineralization (part 3). J Clin Pediatr Dent 2004; 28:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/39\">",
"      Caufield PW, Dasanayake AP, Li Y. The antimicrobial approach to caries management. J Dent Educ 2001; 65:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/40\">",
"      Forgie AH, Paterson M, Pine CM, et al. A randomised controlled trial of the caries-preventive efficacy of a chlorhexidine-containing varnish in high-caries-risk adolescents. Caries Res 2000; 34:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/41\">",
"      DePaola PF, Jordan HV, Soparkar PM. Inhibition of dental caries in school children by topically applied vancomycin. Arch Oral Biol 1977; 22:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/42\">",
"      Smith DJ. Dental caries vaccines: prospects and concerns. Expert Rev Vaccines 2010; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/53/20313/abstract/43\">",
"      Beirne P, Forgie A, Worthington HV, Clarkson JE. Routine scale and polish for periodontal health in adults. Cochrane Database Syst Rev 2005; :CD004625.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3416 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20313=[""].join("\n");
var outline_f19_53_20313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H172605008\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Orofacial space infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Buccal and submental spaces",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Masticator spaces",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Canine and infratemporal spaces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Osteomyelitis of the jaw",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hematogenous dissemination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Association with cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Specimen collection and processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THERAPEUTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dental caries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulpitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute gingivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Periodontitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Suppurative odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H370943006\">",
"      ANTIMICROBIAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172605008\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3416\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3416|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/14/6368\" title=\"figure 1\">",
"      Spread odontogenic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/23/372\" title=\"figure 2\">",
"      Fascial spaces mouth and face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/4/35907\" title=\"figure 3\">",
"      Types of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3416|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/14/25837\" title=\"table 1\">",
"      Symptoms of odontogenic infx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/14/1261\" title=\"table 2\">",
"      Caries periodontitis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/38/39532\" title=\"table 3\">",
"      Treatment of odontogenic infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21559?source=related_link\">",
"      Cervicofacial actinomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18777?source=related_link\">",
"      Gingivitis and periodontitis in adults: Classification and dental treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_53_20314="Cytarabine: Drug information";
var content_f19_53_20314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cytarabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/27/13749?source=see_link\">",
"    see \"Cytarabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"    see \"Cytarabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cytarabine Injection;",
"     </li>",
"     <li>",
"      Cytosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute myeloid leukemia (AML) remission induction:",
"     </b>",
"     I.V.: Standard-dose (provided in the FDA-approved labeling): 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 7 days",
"     <b>",
"      or",
"     </b>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion (as 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 12 hours every 12 hours) for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Indication-specific dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      AML induction:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      7 + 3 regimens (a second induction course may be administered if needed; refer to specific references):",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 7 days (in combination with daunorubicin",
"     <b>",
"      or",
"     </b>",
"     idarubicin",
"     <b>",
"      or",
"     </b>",
"     mitoxantrone) (Arlin, 1990; Dillman, 1991; Fernandez, 2009; Wiernick, 1992)",
"     <b>",
"      or",
"     </b>",
"     (Adults &lt;60 years) 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 7 days (in combination with daunorubicin) (Dillman, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Low intensity therapy (unlabeled dosing):",
"     </i>",
"     Adults &ge;65 years: SubQ: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 14 days out of every 28-day cycle  for at least 4 cycles (Fenaux, 2010)",
"     <b>",
"      or",
"     </b>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours for 21 days; if complete response not achieved, may repeat a second course after 15 days (Tilly, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      AML consolidation (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      5 + 2 regimens:",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days (in combination with daunorubicin",
"     <b>",
"      or",
"     </b>",
"     idarubicin",
"     <b>",
"      or",
"     </b>",
"     mitoxantrone) (Arlin, 1990; Wiernick, 1992)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      5 + 2 + 5 regimen:",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days (in combination with daunorubicin",
"     <b>",
"      and",
"     </b>",
"     etoposide) (Bishop, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Single-agent:",
"     </i>",
"     Adults &le;60 years: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 12 hours on days 1, 3, and 5 (total of 6 doses); repeat every 28-35 days for 4 courses (Mayer, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      AML salvage treatment (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      ADE regimen:",
"     </i>",
"     Course 1: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V push every 12 hours for 10 days (in combination with daunorubicin and etoposide) followed by Course 2: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V push every 12 hours for 8 days (Milligan, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      CLAG regimen:",
"     </i>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 5 days (in combination with cladribine and G-CSF); may repeat once if needed (Wrzesie -Ku, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      CLAG-M regimen:",
"     </i>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 5 days (in combination with cladribine, G-CSF, and mitoxantrone); may repeat once if needed (Wierzbowska, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      FLAG regimen:",
"     </i>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (Montillo, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      HiDAC (high-dose cytarabine) &plusmn; an anthracycline:",
"     </i>",
"     3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 1 hour every 12 hours for 12 doses (Herzig, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      MEC regimen:",
"     </i>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 6 hours for 6 days (in combination with mitoxantrone and etoposide) (Amadori, 1991)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults &lt;60 years: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1, 2, and 3 and days 8, 9, and 10 (in combination with mitoxantrone and etoposide); may administer a second course if needed (Archimbaud, 1991; Archimbaud, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute promyelocytic leukemia (APL) induction (unlabeled dosing):",
"     </b>",
"     I.V.: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 7 days beginning on day 3 of treatment (in combination with tretinoin and daunorubicin) (Ades, 2006; Powell, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      APL consolidation (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      In combination with idarubicin and tretinoin:",
"     </i>",
"     High-risk patients (WBC &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) (Sanz, 2010): Adults &le;60 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     First consolidation course: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4  days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Third consolidation course: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      In combination with idarubicin, tretinoin, and thioguanine:",
"     </i>",
"     High-risk patients (WBC &gt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) (Lo Coco, 2010): Adults &le;61 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     First consolidation course: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Third consolidation course: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      In combination with daunorubicin",
"     </i>",
"     (Ades, 2006; Ades, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     First consolidation course: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Second consolidation course:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Age &le;60 years and low risk (WBC &lt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours for 4 days (8 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Age &lt;50 years and high risk (WBC &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours for 5 days (10 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Age 50-60 years and high risk (WBC &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours for 5 days (10 doses) (Ades, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Age &gt;60 years and high risk (WBC &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours for 4 days (8 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute lymphocytic leukemia (ALL; unlabeled dosing):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Induction regimen, relapsed or refractory:",
"     </i>",
"     I.V.: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours daily for 5 days (in combination with idarubicin [day 3]) (Weiss, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Dose-intensive regimen:",
"     </i>",
"     I.V.: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 2 hours every 12 hours  days 2 and 3 (4 doses/cycle) of even numbered cycles (in combination with methotrexate; alternates with Hyper-CVAD) (Kantarjian, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Larson regimen",
"     </i>",
"     (Larson, 1995): SubQ",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Early intensification phase: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1-4 and 8-11 (4-week cycle; repeat once)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Late intensification phase: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 29-32 and 36-39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Linker protocol:",
"     </i>",
"     I.V.: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1, 4, 8, and 11 of even numbered consolidation  cycles (in combination with teniposide) (Linker, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic lymphocytic leukemia (CLL; unlabeled use):",
"     </b>",
"     <i>",
"      OFAR regimen:",
"     </i>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 2 hours days 2 and 3 every 4 weeks for up to 6 cycles (in combination with oxaliplatin, fludarabine, and rituximab) (Tsimberidou, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic myeloid leukemia (CML; unlabeled dosing):",
"     </b>",
"     SubQ: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 15-24 every month (in combination with interferon alfa-2b) (Guilhot, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      CNS lymphoma, primary (unlabeled use):",
"     </b>",
"     I.V.: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 1 hour every 12 hours days 2 and 3 (total of 4 doses) every 3 weeks (in combination with methotrexate and followed by whole brain irradiation) for a total of 4 courses (Ferreri, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma, relapsed or refractory (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      DHAP regimen:",
"     </i>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 12 hours day 2 (total of 2 doses/cycle) for 2 cycles (in combination with dexamethasone and cisplatin) (Josting, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      ESHAP regimen:",
"     </i>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 5 (in combination with etoposide, methylprednisolone,  and cisplatin) every 3-4 weeks for 3 or 6 cycles (Aparicio, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Mini-BEAM regimen:",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours days 2-5 (total of 8 doses) every 4-6 weeks (in combination with carmustine, etoposide, and melphalan) (Colwill, 1995; Martin, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      BEAM regimen (transplant preparative regimen):",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily for 4 days beginning 5 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (Chopra, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin&rsquo;s lymphomas (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      CALGB 9251 regimen:",
"     </i>",
"     Cycles 2, 4, and 6: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 4 and 5 (Lee, 2001; Rizzieri, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      CODOX-M/IVAC regimen:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults &le;60 years: Cycles 2 and 4 (IVAC): 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (Magrath, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults &le;65 years: Cycles 2 and 4 (IVAC): 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (Mead, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults &gt;65 years: Cycles 2 and 4 (IVAC): 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (Mead, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      DHAP regimen:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults &le;70 years: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3-4 weeks for 6-10 cycles (in combination with dexamethasone and cisplatin) (Velasquez, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults &gt;70 years: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3-4 weeks for 6-10 cycles (in combination with dexamethasone and cisplatin) (Velasquez, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      ESHAP regimen:",
"     </i>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 2 hours day 5 every 3-4 weeks for 6-8 cycles (in combination with etoposide, methylprednisolone, and cisplatin) (Velasquez, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      BEAM regimen (transplant preparative regimen):",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily for 3 days beginning 4 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (Linch 2010)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 1 hour every 12 hours for 4 days beginning 5 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (van Imhoff, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Meningeal leukemia:",
"     </b>",
"     I.T.:",
"     <b>",
"      Note:",
"     </b>",
"     Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer, 1983; Kerr, 2001). Dosing provided in the FDA-approved labeling is BSA-based (usual dose 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 days; range: 5-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 4 days or once every 4 days until CNS findings normalize, followed by 1 additional treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Unlabeled uses or doses for intrathecal therapy:",
"     </b>",
"     I.T.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CNS prophylaxis (ALL):",
"     </i>",
"     100 mg weekly for 8 doses, then every 2 weeks for 8 doses, then monthly for 6 doses (high-risk patients)",
"     <b>",
"      or",
"     </b>",
"     100 mg on day 7 or 8 with each chemotherapy cycle for 4 doses (low risk patients)",
"     <b>",
"      or",
"     </b>",
"     16 doses (high-risk patients) (Cortes, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"     as part of intrathecal triple therapy (TIT): 40 mg days 0 and 14 during induction, days 1, 4, 8, and 11 during CNS therapy phase, every 18 weeks during intensification and maintenance phases (Storring, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CNS prophylaxis (APL, as part of TIT):",
"     </i>",
"     50 mg per dose; administer 1 dose prior to consolidation and 2 doses during each of 2 consolidation phases (total of 5 doses) (Ades, 2006; Ades, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CNS leukemia treatment (ALL, as part of TIT):",
"     </i>",
"     40 mg twice weekly until CSF cleared (Storring, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CNS lymphoma treatment:",
"     </i>",
"     50 mg twice a week for 4 weeks, then weekly for 4-8 weeks, then every other week for 4 weeks, then every 4 weeks for 4 doses (Glantz, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Leptomeningeal metastases treatment",
"     </i>",
"     : 50 mg twice a week for 4 weeks, then weekly for 4 weeks then monthly for 4 doses (NCCN CNS cancer guidelines v.1.2010)",
"     <b>",
"      or",
"     </b>",
"     40-60 mg per dose (DeAngelis, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F156029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"      see \"Cytarabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute myeloid leukemia (AML) remission induction:",
"     </b>",
"     I.V.: Standard-dose (provided in the FDA-approved labeling): 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 7 days",
"     <b>",
"      or",
"     </b>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion (as 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 12 hours every 12 hours) for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      AML induction:",
"     </b>",
"     <i>",
"      7 + 3 regimen:",
"     </i>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &lt;3 years (unlabeled dosing): 3.3 mg/kg/day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin) (Woods, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &ge;3 years: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin) (Woods, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      AML consolidation (unlabeled use):",
"     </b>",
"     <i>",
"      5 + 2 + 5 regimen:",
"     </i>",
"     I.V.: Children &ge;15 years: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days for 2 consolidation courses (in combination with daunorubicin and etoposide) (Bishop, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      AML salvage treatment (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      FLAG regimen:",
"     </i>",
"     I.V.: Children &ge;11 years: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (Montillo, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      MEC regimen:",
"     </i>",
"     I.V.: Children &ge;5 years: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 6 hours for 6 days (in combination with etoposide and mitoxantrone) (Amadori, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute lymphocytic leukemia (ALL; unlabeled dosing):",
"     </b>",
"     <i>",
"      POG 8602/PVA regimen, intensification phase:",
"     </i>",
"     I.V.: Children &ge;1 year: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     continuous infusion over 24 hours day 1 (beginning 12 hours after start of methotrexate) every 3 weeks or every 12 weeks for 6 cycles (Land, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic myeloid leukemia (CML; unlabeled dosing):",
"     </b>",
"     SubQ: Children &ge;7 years: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily days 15-24 every month (in combination with interferon alfa-2b) (Guilhot, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin&rsquo;s lymphomas (unlabeled use):",
"     </b>",
"     <i>",
"      CODOX-M/IVAC regimen:",
"     </i>",
"     I.V.: Children &ge;3 years: Cycles 2 and 4 (IVAC): 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna and etoposide; IVAC alternates with CODOX-M) (Magrath, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Meningeal leukemia:",
"     </b>",
"     I.T.:",
"     <b>",
"      Note:",
"     </b>",
"     Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer, 1983; Kerr, 2001). Dosing provided in the FDA-approved labeling is BSA-based (usual dose 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 days; range: 5-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 4 days or once every 4 days until CNS findings normalize, followed by 1 additional treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Age-based intrathecal dosing (unlabeled):",
"     </b>",
"     I.T.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CNS prophylaxis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;1 year: 20 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1 to 1.99 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2 to 2.99 years: 50 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;3 years: 70 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      ALL CNS prophylaxis, age-specific doses from literature:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Administer on day 0 of induction therapy (Gaynon, 1993):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1 to &lt;2 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     2 to &lt;3 years: 50 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;3 years: 70 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Administer as part of triple intrathecal therapy (TIT) on days 1 and 15 of induction therapy; days 1, 15, 50, and 64 (standard risk patients) or days 1, 15, 29, and 43 (high-risk patients) during consolidation therapy; day 1 of reinduction therapy, and during maintenance therapy (very high-risk patients receive on days 1, 22, 45, and 59 of induction, days 8, 22, 36, and 50 of consolidation therapy, days 8 and 38 of reinduction therapy, and during maintenance) (Lin, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;1 year: 18 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1-2 years: 24 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     2-3 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;3 years: 36 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Administer on day 0 of induction therapy, then as part of TIT on days 7, 14, and 21 during consolidation therapy; as part of TIT on days 0, 28, and 35 for 2 cycles of delayed intensification therapy, and then maintenance treatment as part of TIT on day 0 every 12 weeks for 38 months (boys) or 26 months (girls) from initial induction treatment (Matloub, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1 to &lt;2 years: 16 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     2 to &lt;3 years: 20 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;3 years: 24-30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Administer on day 15 of induction therapy, days 1 and 15 of reinduction phase; and day 1 of cycle 2 of maintenance 1A phase (Pieters, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;1 year: 15 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;1 year: 20 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Treatment, CNS leukemia (ALL):",
"     </i>",
"     I.T.: Administer as part of TIT weekly until CSF remission, then every 4 weeks throughout continuation treatment (Lin, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;1 year: 18 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-2 years: 24 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-3 years: 30 mg per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;3 years: 36 mg per dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F156004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain renal dosing adjustment guidelines; the following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007 (cytarabine 100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Children and Adults: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kintzel, 1995 (high-dose cytarabine 1-3 g/m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 60% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Consider use of alternative drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Smith, 1997 (high-dose cytarabine; &ge;2 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum creatinine 1.5-1.9 mg/dL or increase (from baseline) of 0.5-1.2 mg/dL: Reduce dose to 1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum creatinine &ge;2 mg/dL or increase (from baseline) of &gt;1.2 mg/dL: Reduce dose to 0.1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day as a continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: In 4 hour dialysis sessions (with high flow polysulfone membrane) 6 hours after cytarabine 1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     over 2 hours, 63% of the metabolite ARA-U was extracted from plasma (based on a single adult case report) (Radeski, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F156005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose may need to be adjusted in patients with liver failure since cytarabine is partially detoxified in the liver. The FDA-approved labeling does not contain hepatic dosing adjustment guidelines; the following guideline has been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Floyd, 2006: Transaminases (any elevation): Administer 50% of dose; may increase subsequent doses in the absence of toxicities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Koren, 1992 (dose level not specified):  Bilirubin &gt;2 mg/dL: Administer 50% of dose; may increase subsequent doses in the absence of toxicities",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 100 mg [contains benzyl alcohol (in diluent)], 500 mg [contains benzyl alcohol (in diluent)], 1 g [contains benzyl alcohol (in diluent)], 2 g [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 20 mg/mL (25 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 20 mg/mL (5 mL, 50 mL); 100 mg/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F155979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse standard dose therapy for AML (100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) as a continuous infusion. Infuse high-dose therapy (unlabeled) over 1-3 hours (usually). Other rates have been used, refer to specific reference.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.T.: Intrathecal doses should be administered as soon as possible after preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     May also be administered SubQ.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amsacrine, anidulafungin, aztreonam, cefepime, chlorpromazine, cimetidine, cladribine, dexamethasone sodium phosphate, diphenhydramine, doxorubicin liposomal, droperidol, etoposide phosphate, famotidine, filgrastim, fludarabine, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, idarubicin, linezolid, lorazepam, melphalan, methotrexate, metoclopramide, morphine, ondansetron, paclitaxel, pemetrexed, piperacillin/tazobactam, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, sodium bicarbonate, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible",
"     </b>",
"     Allopurinol, caspofungin, gallium nitrate, ganciclovir.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, methylprednisolone sodium succinate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Metoclopramide, triple intrathecal therapy (TIT) (cytarabine 30-50 mg with hydrocortisone sodium succinate 15-25 mg and methotrexate 12 mg).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remission induction in acute myeloid leukemia (AML), treatment of acute lymphocytic leukemia (ALL) and chronic myelocytic leukemia (CML; blast phase); prophylaxis and treatment of meningeal leukemia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10570465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     AML consolidation treatment, AML salvage treatment; acute promyelocytic leukemia (APL) consolidation treatment; treatment of primary central nervous system (CNS) lymphoma; treatment of chronic lymphocytic leukemia (CLL); treatment of relapsed or refractory Hodgkin lymphoma; treatment of non-Hodgkin&rsquo;s lymphomas (NHL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytarabine may be confused with clofarabine, Cytosar&reg;, Cytoxan, vidarabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytarabine (conventional) may be confused with cytarabine liposomal",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytosar-U may be confused with cytarabine, Cytovene&reg;, Cytoxan, Neosar",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       <i>",
"        Intrathecal medication safety:",
"       </i>",
"       The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Intrathecal medication should not be prepared during the preparation of any other agents",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; After preparation, store in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Frequent:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anal inflammation, anal ulceration, anorexia, diarrhea, mucositis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression, neutropenia (onset: 1-7 days; nadir [biphasic]: 7-9 days and at 15-24 days; recovery [biphasic]: 9-12 days and at 24-34 days), thrombocytopenia (onset: 5 days; nadir: 12-15 days; recovery 15-25 days), anemia, bleeding, leukopenia, megaloblastosis, reticulocytes decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic dysfunction, transaminases increased (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Less frequent:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, neural toxicity, neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, pruritus, skin freckling, skin ulceration, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, bowel necrosis, esophageal ulceration, esophagitis, pancreatitis, sore throat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site cellulitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic edema, anaphylaxis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infrequent and/or case reports:",
"     </b>",
"     Acute respiratory distress syndrome, amylase increased, angina, aseptic meningitis, cardiopulmonary arrest (acute), cerebral dysfunction, cytarabine syndrome (bone pain, chest pain, conjunctivitis, fever, maculopapular rash, malaise, myalgia); exanthematous pustulosis, hepatic sinusoidal obstruction syndrome (SOS; veno-occlussive disease), hyperuricemia, injection site inflammation (SubQ injection), injection site pain (SubQ injection), interstitial pneumonitis, lipase increased, paralysis (intrathecal and I.V. combination therapy), reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, toxic megacolon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adverse events associated with high-dose cytarabine",
"     </b>",
"     (CNS, gastrointestinal, ocular, and pulmonary toxicities are more common with high-dose regimens):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Cardiomegaly, cardiomyopathy (in combination with cyclophosphamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Cerebellar toxicity, coma, neurotoxicity (up to 55% in patients with renal impairment), personality change, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Alopecia (complete), desquamation, rash (severe)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal ulcer, pancreatitis, peritonitis, pneumatosis cystoides intestinalis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia, liver abscess, liver damage, necrotizing colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (motor and sensory)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Corneal toxicity, hemorrhagic conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pulmonary edema, syndrome of sudden respiratory distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adverse events associated with intrathecal cytarabine administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Accessory nerve paralysis, fever, necrotizing leukoencephalopathy (with concurrent cranial irradiation, I.T. methotrexate, and I.T. hydrocortisone), neurotoxicity, paraplegia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blindness (with concurrent systemic chemotherapy and cranial irradiation), diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, hoarseness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Aphonia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cytarabine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F155965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Myelosuppression (leukopenia, thrombocytopenia and anemia) is the major toxicity of cytarabine.",
"     </b>",
"     Use with caution in patients with prior drug-induced bone marrow suppression. Monitor blood counts frequently; once blasts are no longer apparent in the peripheral blood, bone marrow should be monitored frequently. Monitor for signs of infection or neutropenic fever due to neutropenia or bleeding due to thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Anaphylaxis resulting in acute cardiopulmonary arrest has been reported (rare).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: There have been reports of acute pancreatitis in patients receiving continuous infusion and in patients previously treated with L-asparaginase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sudden respiratory arrest syndrome: Syndrome may occur 6-12 hours following administration and characterized by fever, myalgia, bone pain, chest pain, maculopapular rash, conjunctivitis, and malaise; may be managed with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome and subsequent hyperuricemia may occur with high-dose therapy; consider allopurinol and hydrate accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at higher risk for CNS toxicities and dosage adjustments may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with impaired renal function (high dose cytarabine); may be at higher risk for CNS toxicities and dosage adjustments may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cyclophosphamide: There have been case reports of fatal cardiomyopathy when high-dose cytarabine was used in combination with cyclophosphamide as a preparation regimen for transplantation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some products may contain benzyl alcohol; do not use products containing benzyl alcohol or products reconstituted with bacteriostatic diluent intrathecally or for high-dose cytarabine regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.  Due to the potential toxicities, induction treatment with cytarabine should be in a facility with sufficient laboratory and supportive resources.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High-dose treatment: High-dose regimens have been associated with GI, CNS, pulmonary, ocular (reversible corneal toxicity and hemorrhagic conjunctivitis; prophylaxis with ophthalmic corticosteroids is recommended) toxicities, and cardiomyopathy. Neurotoxicity associated with high-dose treatment may present as acute cerebellar toxicity (with or without cerebral impairment), personality changes, or may be severe with seizure and/or coma; may be delayed, occurring up to 3-8 days after treatment has begun; possibly irreversible. Risk factors for neurotoxicity include cumulative cytarabine dose, prior CNS disease and renal impairment (incidence may be up to 55% in patients with renal impairment); high-dose therapy (&gt;18 g/m",
"     <sup>",
"      2",
"     </sup>",
"     per cycle) and age &gt;50 years also increase the risk for cerebellar toxicity (Herzig, 1987).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrathecal safety: When used for intrathecal administration, should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the central nervous system (Jacobson, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucytosine: Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F155985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were demonstrated in animal studies; limb and ear defects have been noted in case reports of cytarabine exposure during the first trimester of pregnancy. The following have also been noted in the neonate: Pancytopenia, WBC depression, electrolyte abnormalities, prematurity, low birth weight, decreased hematocrit or platelets. Risk to the fetus is decreased if treatment can be avoided during the first trimester; however, women of childbearing potential should be advised of the potential risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5375699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cytarabine (PF) Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $6.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cytarabine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (25 mL): $14.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (20 mL): $24.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cytarabine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $27.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $9.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F155974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, CBC with differential and platelet count, serum creatinine, BUN, serum uric acid",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alexan (AT, BG, BR, CH, CN, CZ, DK, EC, GB, HK, HN, HR, HU, ID, IE, IT, PL, PT, RU, SE, TH, TR, ZA);",
"     </li>",
"     <li>",
"      Ara-C (AR);",
"     </li>",
"     <li>",
"      Arabine (DK, FI, FR);",
"     </li>",
"     <li>",
"      Arabitin (JP);",
"     </li>",
"     <li>",
"      Aracytin (CO, GR, IT, UY);",
"     </li>",
"     <li>",
"      Aracytine (FR);",
"     </li>",
"     <li>",
"      Cancyt (PH);",
"     </li>",
"     <li>",
"      Citafam (AR);",
"     </li>",
"     <li>",
"      Citarabina (ES);",
"     </li>",
"     <li>",
"      Cyclocide (TW);",
"     </li>",
"     <li>",
"      Cylocide (JP);",
"     </li>",
"     <li>",
"      Cytarabin (DE, NO);",
"     </li>",
"     <li>",
"      Cytarabine (AU);",
"     </li>",
"     <li>",
"      Cytarabine Injection (AU, GB, NZ);",
"     </li>",
"     <li>",
"      Cytarabinum-Delta West (LU);",
"     </li>",
"     <li>",
"      Cytarine (IN, SG, TH);",
"     </li>",
"     <li>",
"      Cytonal (RU, TR);",
"     </li>",
"     <li>",
"      Cytosa U (KP);",
"     </li>",
"     <li>",
"      Cytosar (AE, AT, BE, BG, BH, CH, CL, CY, CZ, EE, EG, FI, GB, GH, HK, HN, HR, HU, IL, IQ, IR, JO, KE, KW, LB, LY, NL, OM, PE, PK, PT, QA, SA, SY, TH, TZ, UG, YE, ZA, ZM);",
"     </li>",
"     <li>",
"      Cytosar-U (ID, KP, MY, VE);",
"     </li>",
"     <li>",
"      Cytox (PH);",
"     </li>",
"     <li>",
"      Laracit (CO, MX);",
"     </li>",
"     <li>",
"      Medsara (MX);",
"     </li>",
"     <li>",
"      Mokcell (PE);",
"     </li>",
"     <li>",
"      Starasid (JP);",
"     </li>",
"     <li>",
"      Tabine (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA synthesis. Cytosine gains entry into cells by a carrier process, and then must be converted to its active compound, aracytidine triphosphate. Cytosine is a pyrimidine analog and is incorporated into DNA; however, the primary action is inhibition of DNA polymerase resulting in decreased DNA synthesis and repair. The degree of cytotoxicity correlates linearly with incorporation into DNA; therefore, incorporation into the DNA is responsible for drug activity and toxicity. Cytarabine is specific for the S phase of the cell cycle (blocks progression from the G",
"     <sub>",
"      1",
"     </sub>",
"     to the S phase).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Total body water; widely and rapidly since it enters the cells readily; crosses blood-brain barrier with CSF levels of 40% to 50% of plasma level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; metabolized by deoxycytidine kinase and other nucleotide kinases to aracytidine triphosphate (active); about 86% to 96% of dose is metabolized to inactive uracil arabinoside (ARA-U); intrathecal administration results in little conversion to ARA-U due to the low levels of deaminase in the cerebral spinal fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: Initial: 7-20 minutes; Terminal: 1-3 hours; I.T.: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: SubQ: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~80%; 90% as metabolite ARA-U) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad&egrave;s L, Chevret S, Raffous, et al, &ldquo;Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2006, 24(36):5703-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/17116939/pubmed\" id=\"17116939\" target=\"_blank\">",
"        17116939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ad&egrave;s L, Sanz MA, Chevret S, et al, &ldquo;Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison of French-Belgian-Swiss and PETHEMA Results,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(3):1078-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/17975017/pubmed\" id=\"17975017\" target=\"_blank\">",
"        17975017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amadori S, Arcese W, Isacchi G, et al, &ldquo;Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine: An Effective and Tolerable Regimen for the Treatment of Refractory Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1991, 9(7):1210-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/2045861/pubmed\" id=\"2045861\" target=\"_blank\">",
"        2045861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aparicio J, Segura A, Garcer&aacute; S, et al, &ldquo;ESHAP is an Active Regimen for Relapsing Hodgkin's Disease,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 1999, 10(5):593-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/10416011/pubmed\" id=\"10416011\" target=\"_blank\">",
"        10416011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Archimbaud E, Leblond V, Michallet M, et al \"&ldquo;Intensive Sequential Chemotherapy With Mitoxantrone and Continuous Infusion Etoposide and Cytarabine for Previously Treated Acute Myelogenous Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1991, 77(9):1894-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/2018832/pubmed\" id=\"2018832\" target=\"_blank\">",
"        2018832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Archimbaud E, Thomas X, Leblond V, et al, \"Timed Sequential Chemotherapy for Previously Treated Patients With Acute Myeloid Leukemia: Long-Term Follow-Up of the Etoposide, Mitoxantrone, and Cytarabine-86 Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(1):11-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/7799010/pubmed\" id=\"7799010\" target=\"_blank\">",
"        7799010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arlin Z, Case DC Jr, Moore J, et al, &ldquo;Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1990, 4(3):177-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/2179638/pubmed\" id=\"2179638\" target=\"_blank\">",
"        2179638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98, 170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bishop JF, Matthews JP, Young GA, et al, \"A Randomized Study of High-Dose Cytarabine in Induction in Acute Myeloid Leukemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 1996, 87(5):1710-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8634416/pubmed\" id=\"8634416\" target=\"_blank\">",
"        8634416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleyer WA, Coccia PF, Sather HN, et al, &ldquo;Reduction in Central Nervous System Leukemia With a Pharmacokinetically Derived Intrathecal Methotrexate Dosage Regimen,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1983, 1(5):317-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/6366138/pubmed\" id=\"6366138\" target=\"_blank\">",
"        6366138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassileth PA, Harrington DP, Appelbaum FR, et al, &ldquo;Chemotherapy Compared With Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(23):1649-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/9834301/pubmed\" id=\"9834301\" target=\"_blank\">",
"        9834301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chiu A, Kohler S, McGuire J, et al, &ldquo;Cytarabine-Induced Acute Generalized Exanthematous Pustulosis,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2002, 47(4):633-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chopra R, McMillan AK, Linch DC, et al, &ldquo;The Place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor-Risk Hodgkin's Disease. A Single-Center Eight-Year Study of 155 Patients,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1993, 81(5):1137-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8443375/pubmed\" id=\"8443375\" target=\"_blank\">",
"        8443375",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colwill R, Crump M, Couture F, et al,, &ldquo;Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease Before Intensive Therapy and Autologous Bone Marrow Transplantation,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(2):396-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/7844600/pubmed\" id=\"7844600\" target=\"_blank\">",
"        7844600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortes J, O&rsquo;Brien SM, Pierce S, et al, &ldquo;The Value of High-Dose Systemic Chemotherapy and Intrathecal Therapy for Central Nervous System Prophylaxis in Different Risk Groups of Adult Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 86(6):2091-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/7662956/pubmed\" id=\"7662956\" target=\"_blank\">",
"        7662956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeAngelis LM and Boutros D, &ldquo;Leptomeningeal Metastasis,&rdquo;",
"      <i>",
"       Cancer Invest",
"      </i>",
"      , 2005, 23(2):145-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/15813508/pubmed\" id=\"15813508\" target=\"_blank\">",
"        15813508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lemos ML, Monfared S, Denyssevych T, et al, &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringers&rsquo;s Solution for Intrathecal Administration,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2009, 15(1):45-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/18772215/pubmed\" id=\"18772215\" target=\"_blank\">",
"        18772215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dillman RO, Davis RB, Green MR, et al, &ldquo;A Comparative Study of Two Different Doses of Cytarabine for Acute Myeloid Leukemia: A Phase III Trial of Cancer and Leukemia Group B,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1991, 78(10):2520-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/1824249 /pubmed\" id=\"1824249 \" target=\"_blank\">",
"        1824249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      D&ouml;hner H, Estey EH, Amadori S, et al, &ldquo;Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations From an International Expert Panel, on Behalf of the European LeukemiaNet,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(3):453-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/19880497/pubmed\" id=\"19880497\" target=\"_blank\">",
"        19880497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al, &ldquo;Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia,",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(4):562-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/20026804/pubmed\" id=\"20026804\" target=\"_blank\">",
"        20026804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez HF, Sun Z, Yao X, et al, &ldquo;Anthracycline Dose Intensification in Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(13):1249-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/19776406/pubmed\" id=\"19776406\" target=\"_blank\">",
"        19776406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferreri AJ, Reni M, Foppoli M, et al, &ldquo;High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients With Primary CNS Lymphoma: a Randomised Phase 2 Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9700):1512-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/19767089/pubmed\" id=\"19767089\" target=\"_blank\">",
"        19767089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardin C, Turlure P, Fagot T, et al, &ldquo;Postremission Treatment of Elderly Patients With Acute Myeloid Leukemia in First Complete Remission After Intensive Induction Chemotherapy: Results of the Multicenter Randomized Acute Leukemia French Association (ALFA) 9803 Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(12):5129-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/17341661/pubmed\" id=\"17341661\" target=\"_blank\">",
"        17341661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaynon PS, Steinherz PG, Bleyer WA, et al, &ldquo;Improved Therapy for Children With Acute Lymphoblastic Leukemia and Unfavorable Presenting Features: A Follow-Up Report of the Childrens Cancer Group Study CCG-106,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(11):2234-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8229139/pubmed\" id=\"8229139\" target=\"_blank\">",
"        8229139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glantz MJ, LaFollette S, Jaeckle KA, et al, &ldquo;Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(10):3110-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/10506606/pubmed\" id=\"10506606\" target=\"_blank\">",
"        10506606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guilhot F, Chastang C, Michallet M, et al, \"Interferon Alfa-2b Combined With Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia. French Chronic Myeloid Leukemia Study Group,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(4):223-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/ 9227927/pubmed\" id=\" 9227927\" target=\"_blank\">",
"        9227927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herzig RH, Hines JD, Herzig GP, et al, &ldquo;Cerebellar Toxicity With High-Dose Cytosine Arabinoside,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1987, 5(6):927-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/3585447/pubmed\" id=\"3585447\" target=\"_blank\">",
"        3585447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herzig RH, Lazarus HM, Wolff SN, et al, &ldquo;High-Dose Cytosine Arabinoside Therapy With and Without Anthracycline Antibiotics for Remission Reinduction of Acute Nonlymphoblastic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1985, 3(7):992-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/3894588/pubmed\" id=\"3894588\" target=\"_blank\">",
"        3894588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hiddemann W, &ldquo;Cytosine Arabinoside in the Treatment of Acute Myeloid Leukemia: The Role and Place of High-Dose Regimens,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 1991, 62(4):119-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/2031974/pubmed\" id=\"2031974\" target=\"_blank\">",
"        2031974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, \"American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Josting A, Rudolph C, Reiser M, et al, &ldquo;Time-Intensified Dexamethasone/Cisplatin/Cytarabine: An Effective Salvage Therapy With Low Toxicity in Patients With Relapsed and Refractory Hodgkin's Disease,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(10):1628-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/12377653/pubmed\" id=\"12377653\" target=\"_blank\">",
"        12377653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al, &ldquo;Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(3): 547-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/10653870 /pubmed\" id=\"10653870 \" target=\"_blank\">",
"        10653870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerr JZ, Berg S, and Blaney SM, &ldquo;Intrathecal Chemotherapy,&rdquo;",
"      <i>",
"       Crit Rev Oncol Hematol",
"      </i>",
"      , 2001, 37(3):227-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/11248578/pubmed\" id=\"11248578\" target=\"_blank\">",
"        11248578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(3):363-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/1554959/pubmed\" id=\"1554959\" target=\"_blank\">",
"        1554959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Land VJ, Shuster JJ, Crist WM, et al, &ldquo;Comparison of Two Schedules of Intermediate-Dose Methotrexate and Cytarabine Consolidation Therapy for Childhood B-Precursor Cell Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(9):1939-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8083715 /pubmed\" id=\"8083715 \" target=\"_blank\">",
"        8083715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(8):2025-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/7718875 /pubmed\" id=\"7718875 \" target=\"_blank\">",
"        7718875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee EJ, Petroni GR, Schiffer CA, et al, &ldquo;Brief-Duration High-Intensity Chemotherapy for Patients With Small Noncleaved-Cell Lymphoma or FAB L3 Acute Lymphocytic Leukemia: Results of Cancer and Leukemia Group B Study 9251,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(20):4014-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/11600602/pubmed\" id=\"11600602\" target=\"_blank\">",
"        11600602",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin WY, Liu HC, Yeh TC, et al, &ldquo;Triple Intrathecal Therapy Without Cranial Irradiation for Central Nervous System Preventive Therapy in Childhood Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(3):523-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/17455314/pubmed\" id=\"17455314\" target=\"_blank\">",
"        17455314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linch DC, Yung L, Smith P, et al, &ldquo;Final Analysis of the UKLG LY02 Trial Comparing 6-8 Cycles of CHOP With 3 Cycles of CHOP Followed by a BEAM Autograft in Patients &lt;65 Years With Poor Prognosis Histologically Aggressive NHL,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2010, 149(2):237-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/20201949/pubmed\" id=\"20201949\" target=\"_blank\">",
"        20201949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linker CA, Levitt LJ, O'Donnell M, et al, &ldquo;Treatment of Adult Acute Lymphoblastic Leukemia With Intensive Cyclical Chemotherapy: A Follow-up Report,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1991, 78(11):2814-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/1835410 /pubmed\" id=\"1835410 \" target=\"_blank\">",
"        1835410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo Coco F, Avvisati G, Vignetti M, et al, &ldquo;Front-Line Treatment of Acute Promyelocytic Leukemia With AIDA Induction Followed by Risk-Adapted Consolidation for Adults Younger Than 61 Years: Results of the AIDA-2000 Trial of the GIMEMA Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(17):3171-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/20644121/pubmed\" id=\"20644121\" target=\"_blank\">",
"        20644121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      L&ouml;wenberg B, Pabst T, Vellenga E, et al, &ldquo;Cytarabine Dose for Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(11):1027-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/21410371/pubmed\" id=\"21410371\" target=\"_blank\">",
"        21410371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Magrath I, Adde M, Shad A, et al, \"Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(3):925-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8622041/pubmed\" id=\"8622041\" target=\"_blank\">",
"        8622041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mart&iacute;n A, Fern&aacute;ndez-Jim&eacute;nez MC, Caballero MD, et al. &ldquo;Long-Term Follow-Up in Patients Treated With Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2001, 113(1):161-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/11328296/pubmed\" id=\"11328296\" target=\"_blank\">",
"        11328296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matloub Y, Lindemulder S, Gaynon PS, et al, &ldquo;Intrathecal Triple Therapy Decreases Central Nervous System Relapse but Fails to Improve Event-Free Survival When Compared With Intrathecal Methotrexate: Results of the Children's Cancer Group (CCG) 1952 Study for Standard-Risk Acute Lymphoblastic Leukemia, Reported by the Children's Oncology Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 108(4):1165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/16609069/pubmed\" id=\"16609069\" target=\"_blank\">",
"        16609069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayer RJ, Davis RB, Schiffer CA, et al, \"Intensive Postremission Chemotherapy in Adults With Acute Myeloid Leukemia, Cancer and Leukemia Group B,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(14):896-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8078551/pubmed\" id=\"8078551\" target=\"_blank\">",
"        8078551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mead GM, Barrans SL, Qian W, et al, \"A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial),\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(6):2248-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/18612102/pubmed\" id=\"18612102\" target=\"_blank\">",
"        18612102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milligan DW, Wheatley K, Littlewood T, et al, &ldquo;Fludarabine and Cytosine are Less Effective than Standard ADE Chemotherapy in High-Risk Acute Myeloid Leukemia, and Addition of G-CSF and ATRA are not Beneficial: Results of the MRC AML-HR Randomized Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(12):4614-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/16484584/pubmed\" id=\"16484584\" target=\"_blank\">",
"        16484584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montillo M, Mirto S, Petti MC, et al, \"Fludarabine, Cytarabine, and G-CSF (FLAG) for the Treatment of Poor Risk Acute Myeloid Leukemia,\"",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1998, 58(2):105-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/9625576/pubmed\" id=\"9625576\" target=\"_blank\">",
"        9625576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&rdquo; Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pease CL, Horton TM, McClain KL, et al, &ldquo;Aseptic Meningitis in a Child After Systemic Treatment With High Dose Cytarabine,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2001, 20(1):87-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/11176579/pubmed\" id=\"11176579\" target=\"_blank\">",
"        11176579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pegram AA and Kennedy LD, &ldquo;Prevention and Treatment of Veno-Occlusive Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2001, 35(7-8):935-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/11485147/pubmed\" id=\"11485147\" target=\"_blank\">",
"        11485147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pieters R, Schrappe M, De Lorenzo P, et al, &ldquo;A Treatment Protocol for Infants Younger Than 1 Year With Acute Lymphoblastic Leukaemia (Interfant-99): An Observational Study and a Multicentre Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9583):240-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/17658395/pubmed\" id=\"17658395\" target=\"_blank\">",
"        17658395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(19):3751-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/20705755/pubmed\" id=\"20705755\" target=\"_blank\">",
"        20705755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Radeski D, Cull GM, Cain M, et al, &ldquo;Effective Clearance of Ara-U the Major Metabolite of Cytosine Arabinoside (Ara-C) by Hemodialysis in a Patient With Lymphoma and End-Stage Renal Failure,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2011, 67(4):765-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/20532508/pubmed\" id=\"20532508\" target=\"_blank\">",
"        20532508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizzieri DA, Johnson JL, Niedzwiecki D, et al, &ldquo;Intensive Chemotherapy With and Without Cranial Radiation for Burkitt Leukemia and Lymphoma: Final Results of Cancer and Leukemia Group B Study 9251,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(7):1438-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/15042678/pubmed\" id=\"15042678\" target=\"_blank\">",
"        15042678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Grimwade D, Tallman MS, et al, &ldquo;Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(9):1875-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/18812465/pubmed\" id=\"18812465\" target=\"_blank\">",
"        18812465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Montesinos P, Ray&oacute;n C, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia Based on all-trans Retinoic Acid and Anthracycline With Addition of Cytarabine in Consolidation Therapy for High-Risk Patients: Further Improvements in Treatment Outcome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(25):5137-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/20393132/pubmed\" id=\"20393132\" target=\"_blank\">",
"        20393132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith G, Damon LE, Rugo HS, et al. &ldquo;High-Dose Cytarabine Dose Modification Reduces the Incidence of Neurotoxicity in Patients With Renal Insufficiency,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(2): 833-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/9053511/pubmed\" id=\"9053511\" target=\"_blank\">",
"        9053511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stasi R, Venditti A, Del Poeta G, et al, &ldquo;High-Dose Chemotherapy in Adult Acute Myeloid Leukemia: Rationale and Results,&rdquo;",
"      <i>",
"       Leuk Res",
"      </i>",
"      , 1996, 20(7):535-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8795687/pubmed\" id=\"8795687\" target=\"_blank\">",
"        8795687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone RM, Berg DT, George SL, et al, &ldquo;Postremission Therapy in Older Patients With",
"      <i>",
"       de novo",
"      </i>",
"      Acute Myeloid Leukemia: A Randomized Trial Comparing Mitoxantrone and Intermediate-Dose Cytarabine With Standard-Dose Cytarabine,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 98(3):548-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/11468148/pubmed\" id=\"11468148\" target=\"_blank\">",
"        11468148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Storring JM, Minden MD, Kao S, et al, &ldquo;Treatment of Adults With BCR-ABL Negative Acute Lymphoblastic Leukaemia With a Modified Paediatric Regimen,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2009, 146(1):76-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/19438471/pubmed\" id=\"19438471\" target=\"_blank\">",
"        19438471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tilly H, Castaigne S, Bordessoule D, et al, &ldquo;Low-Dose Cytarabine Versus Intensive Chemotherapy in the Treatment of Acute Nonlymphocytic Leukemia in the Elderly,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1990, 8(2):272-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/2299370/pubmed\" id=\"2299370\" target=\"_blank\">",
"        2299370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, King KM, Zhang Y, et al, &ldquo;Physical and Chemical Stability of Methotrexate, Cytarabine, and Hydrocortisone in Elliott's B Solution for Intrathecal Use,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2002, 8(1):27-32.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Truica CI and Frankel SR, &ldquo;Acute Rhabdomyolysis as a Complication of Cytarabine Chemotherapy for Acute Myeloid Leukemia: Case Report and Review of Literature,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2002, 70(4):320-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/12210815/pubmed\" id=\"12210815\" target=\"_blank\">",
"        12210815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsimberidou AM, Wierda WG, Plunkett W, et al, \"Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(2):196-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/18182662/pubmed\" id=\"18182662\" target=\"_blank\">",
"        18182662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Imhoff GW, van der Holt B, MacKenzie MA, et al, &ldquo;Short Intensive Sequential Therapy Followed by Autologous Stem Cell Transplantation in Adult Burkitt, Burkitt-Like and Lymphoblastic Lymphoma,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2005, 19(6):945-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/15800666/pubmed\" id=\"15800666\" target=\"_blank\">",
"        15800666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Velasquez WS, Cabanillas F, Salvador P, et al, &ldquo;Effective Salvage Therapy for Lymphoma With Cisplatin in Combination With High-Dose Ara-C and Dexamethasone (DHAP),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1988, 71(1):117-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/3334893 /pubmed\" id=\"3334893 \" target=\"_blank\">",
"        3334893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Velasquez WF, McLaughlin P, Tucker S, et al, &ldquo;ESHAP - An Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-Year Follow-up Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(6):1169-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/8201379 /pubmed\" id=\"8201379 \" target=\"_blank\">",
"        8201379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss MA, Aliff TB, Tallman MS, et al, &ldquo;A Single, High Dose of Idarubicin Combined With Cytarabine as Induction Therapy for Adult Patients With Recurrent or Refractory Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(3):581-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/12209751/pubmed\" id=\"12209751\" target=\"_blank\">",
"        12209751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wierzbowska A, Robak T, Pluta A, et al, &ldquo;Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group,&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      2008; 80(2):115-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/18076637/pubmed\" id=\"18076637\" target=\"_blank\">",
"        18076637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiernik PH, Banks P, Case Jr DC, et al, &ldquo;Cytarabine Plus Idarubicin or Daunorubicin as Induction and Consolidation Therapy for Previously Untreated Adult Patients With Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1992, 79(2):313-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/1730080/pubmed\" id=\"1730080\" target=\"_blank\">",
"        1730080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wittbrodt ET and Aviles VM, &ldquo;Pancreatitis and Fatal ARDS Following High-Dose Cytarabine Induction for Acute Myelogenous Leukemia,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 1997, 3(2):110-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woods WG, Ruymann FB, Lampkin BC, et al, &ldquo;The Role of Timing of High-Dose Cytosine Arabinoside Intensification and of Maintenance Therapy in the Treatment of Children With Acute Nonlymphocytic Leukemia,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1990, 66(6):1106-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/2205352/pubmed\" id=\"2205352\" target=\"_blank\">",
"        2205352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wrzesie-Ku A, Robak T, Lech-Marada E, et al, &ldquo;A Multicenter, Open, Non-Comparative Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia &ndash; A Report of the Polish Adult Leukemia Group (PALG),&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2003;71(3):155&ndash;62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/53/20314/abstract-text/12930315/pubmed\" id=\"12930315\" target=\"_blank\">",
"        12930315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9314 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20314=[""].join("\n");
var outline_f19_53_20314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708668\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156050\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156002\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156029\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156003\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156004\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156005\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155976\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155961\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155979\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156056\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155977\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10570465\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156059\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156048\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155982\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155965\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299114\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155970\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155972\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155985\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156014\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5375699\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323088\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155974\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155986\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155964\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155981\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9314|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/27/13749?source=related_link\">",
"      Cytarabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=related_link\">",
"      Cytarabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_53_20315="Sx of gonadotroph adenomas";
var content_f19_53_20315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical presentations of gonadotroph adenomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic symptoms (most common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other (including diplopia, seizures, and CSF rhinorrhea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Incidental finding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When an imaging procedure is performed because of an unrelated symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypopituitarism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biochemical evidence (most common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical symptoms (less common, but include oligomenorrhea or amenorrhea in women, decreased libido and/or erectile dysfunction in men)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical syndromes due to hormonal hypersecretion (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian hyperstimulation when FSH is secreted excessively in a premenopausal woman",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature puberty when intact LH is secreted in a prepubertal boy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20315=[""].join("\n");
var outline_f19_53_20315=null;
var title_f19_53_20316="Skin lesions SLE";
var content_f19_53_20316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Skin lesions associated with lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        I. Specific skin disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A. Localized Acute Cutaneous LE (ACLE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Localized ACLE (malar rash, butterfly rash)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Inflammatory periorbital edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Mucous membrane lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Oral and nasopharyngeal ulceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Alopecia (fractured frontal hair, scarring and nonscarring alopecia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        B. Generalized ACLE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Disseminated maculopapular eruption &plusmn; butterfly rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Photosensitive lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Toxic epidermal necrolysis-like eruption (apoptotic panepidermal necrolysis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Bullous SLE (epidermolysis bullosa acquisita)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        C. Subacute Cutaneous LE (SCLE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Annular SCLE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Papulosquamous SCLE (psoriasiform, pityriasiform, and photosensitive LE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        D. Chronic Cutaneous LE (CCLE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Classical discoid LE (localized or generalized)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Hypertrophic/verrucous discoid LE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Lupus profundus/lupus panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Mucosal discoid LE (oral or conjunctival)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Lupus tumidius (tumid LE, urticarial plaque of LE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. Chilblains LE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. Lichenoid discoid LE (LE/lichen planus overlap)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8. Palmar-plantar DLE",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel L Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20316=[""].join("\n");
var outline_f19_53_20316=null;
var title_f19_53_20317="NH4 excretion and urine pH";
var content_f19_53_20317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    pH and ammonium excretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 235px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of urinary and arterial pH on NH4+ excretion. Lowering the arterial pH (that is, acidemia) increases cellular NH4+ production from glutamine. Lowering the urine pH enhances the trapping of NH3 as NH4+ in the medullary collecting tubule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pitts, RF, Fed Proc, 7:418, 1948.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20317=[""].join("\n");
var outline_f19_53_20317=null;
var title_f19_53_20318="Cycles of anthrax";
var content_f19_53_20318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infectious cycles of B. anthracis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 371px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anthrax is part of the normal soil flora and, under appropriate conditions, can multiply to increase the number of soil organisms. Grazing animals can become infected and further increase the soil contamination as infected secretions with sporulating B. anthracis are shed. Animals that are ill or dying from anthrax can infect humans who either slaughter or consume contaminated meat. Raw materials, such as hides, hair, or bones, from animals that have died from anthrax are heavily contaminated with anthrax spores. These products can serve as a reservoir for human infection as they are used in a variety of manufacturing processes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20318=[""].join("\n");
var outline_f19_53_20318=null;
var title_f19_53_20319="Biliary atresia type 2";
var content_f19_53_20319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Biliary atresia type 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biliary atresia type 2. Visualization of a narrow and irregular distal common bile duct. Normal cystic duct and gallbladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright &copy; 1997 Taylor and Francis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_53_20319=[""].join("\n");
var outline_f19_53_20319=null;
